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ABSTRACT 
New strategies for treatment and methods of drug delivery are required for 
patients suffering from cancer-the second leading cause of death worldwide. Current 
chemotherapeutic treatments frequently suffer from poor water solubility, systemic 
toxicity, poor accumulation within the target tissues and an inability to eradicate all 
remaining tumor following resection procedures. Nanoparticles (NPs) are extensively 
investigated as a means to increase drug solubility, alter biodistribution, target specific 
sites within the body, and minimize drug side effects and, as such, numerous NP 
formulations are being investigated as drug delivery devices to assist in the treatment and 
management of cancer. We have developed a pH-responsive expansile nanoparticle 
(eNP) that can encapsulate the hydrophobic chemotherapeutic agent Paclitaxel (Pax) (a 
poorly water soluble, yet potent chemotherapeutic agent), and deliver it specifically to the 
intracellular compartment of tumor cells. Paclitaxel-loaded-eNPs (Pax-eNPs) localize 
specifically to regions of intraperitoneal (IP) tumors and, once taken up by tumor cells, 
undergo a conformational change upon exposure to the mildly acidic cellular endosome 
ix 
that results in eNP swelling and intratumoral drug release. In this work, we describe: 1) 
the clinical problem and cost (both humanitarian and fmancial) of local cancer recurrence 
following tumor resection; 2) the eNP delivery system and, specifically, we characterize 
the swelling of eNPs using microscopy and tunable resistive pulse sensing techniques; 3) 
the in vitro activity of Pax-eNPs in breast cancer cells; 4) the improved efficacy of Pax-
eNPs compared to the standard clinical formulation of Pax (i.e., Pax dissolved in 
Cremophor/Ethanol) in a murine model of established peritoneal mesothelioma; and, 5) 
the ability of eNPs to act as intratumoral, intracellular drug concentrating devices. Further 
investigation of this NP-based drug delivery system will facilitate a greater understanding 
of the materials and devices used in the delivery of chemotherapeutic agents and may 
lead to the clinical translation and application of eNPs. 
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CHAPTER 1: The Problem of Local Cancer Recurrence Following Surgical 
Resection 
1.1 Chapter Forward 
This chapter originated from extensive background research conducted for our 
cancer-related drug-delivery grants. In particular, our work focuses on the problem of 
eliminating local cancer recurrence following surgical resection. Cancer patients are 
frequently diagnosed at a late stage in their disease progression, at which point they are 
not considered candidates for curative surgical interventions. However, patients who, at 
the time of diagnosis, are thought to have curable disease will undergo surgical resection 
and may also receive chemo- or radiation-therapy. Unfortunately, even among these 
"curable" patients, local tumor recurrence is a significant problem, as described in this 
chapter. In the course of researching and describing this problem, we have found a void 
in the literature with no thorough reviews regarding the cost, both fmancial and 
humanitarian, of local recurrence following tumor resection. The aim of this chapter, 
which will serve as the basis for a review publication, is to more clearly define this 
problem for researchers and clinicians. 
I am grateful to Meredith Mintzer, Ph.D., who spent significant amounts of time 
pulling the data, facts , and figures that formed much of the foundation of this review. 
1 
1.2 Introduction 
Solid cancers will have been diagnosed in over 1.5 million individuals in 2011 , 
and nearly 500,000 patients will die from cancer-related disease by the year's end. 1 While 
cancer treatments have significantly improved since the "War on Cancer" was initiated in 
the 1970s, cancer recurrence following "curative" therapies is still a major problem that 
significantly lowers the survival rates of patients.Z-3 
Patients who are candidates for curative therapies are most often those with 
locally contained disease capable of being removed by cytoreductive surgery (see Table 
1.1 , 5-year survival for local disease). Surgery is frequently supplemented by local 
radiation therapy; however, target fields are often limited by nearby critical structures and 
prior radiation exposure leading to suboptimal treatment. Due to the localized nature of 
the disease, systemic therapies (e.g., parenteral chemotherapy) are used less frequently as 
they provide negligible benefit to survival while diminishing the patient's quality-of-life 
(QoL). 
It is suggested that the subset of patients who receive "curative" therapies but 
nevertheless develop recurrent tumors do so because of: 1) incomplete surgical resection; 
and/or, 2) insufficient local doses of adjuvant (e.g. radiation) therapy. When these 
patients recur, treatments may include systemic chemotherapy or other targeted therapies 
aimed at slowing or limiting disease progression. However, the aggressiveness of these 
treatments is frequently limited by comorbid conditions.4 Furthermore, while "targeted" 
therapies (e.g. treatments relying on overexpression of specific antibodies or receptors on 
the tumor cell surface) have recently become favorable alternatives to traditional 
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systemic treatments, a nearly universal problem is the development of resistance and 
subsequent "escape" of the tumor resulting in eventual recurrence. 
In the following sections, we examine the impact of local tumor recurrence in 
patients with breast and mesothelioma cancers, as these are the primary applications of 
the subsequent chapters. We also briefly examine other cancers where local recurrence is 
especially problematic, including: lung cancer, colorectal cancer, and soft tissue 
sarcomas. 
1.3 Breast Cancer 
For over a century, surgeons have sought to balance the need to prevent breast 
cancer recurrence following cytoreductive surgery with the desire to reduce morbidity, 
improve cosmetic outcomes and patient QoL. Radical mastectomies were initially used at 
the end of the 19111 century due to the belief that recurrence resulted from inadequate 
tumor removal.5-7 However, the operative mortality and significant morbidity associated 
with radical mastectomies promoted the use of more conservative surgical strategies by 
the late 1930s. 8 As data from these patients became available, no difference was observed 
in the 1 0-year overall survival of those who received radical mastectomies compared to 
those who received less invasive, simple mastectomies while morbidities (e.g., wound 
healing, tissue toleration, edema of the arm) were significantly reduced. As a result, 
radical mastectomies began to fall out of practice. 9 
Beginning in the late 1930s and early 1940s, radiation therapy (RT) was 
3 
introduced to control local disease progression in the axillary nodes. It was observed that 
while node-negative patients demonstrated superior outcomes to node-positive patients, 
surgical removal of the axilla in node-positive patients provided no improvement to 
survival. 10 It was believed that dissection of the axillary nodes resulted in tumor seeding 
and, as a result, RT was used instead. The combination of RT and simple mastectomy 
improved the survival rate of patients receiving a mastectomy from 35-45% to 62%. 10 
The trend in surgical procedures has continued toward removal of less tissue with 
breast-conserving surgery (BCS) replacing simple mastectomy for patients with localized 
disease. RT is used to complement BCS and this combination (BCS + RT) has become 
standard practice for treating breast cancer. Results from a 20-year follow-up study show 
that the chance of contralateral disease or distant metastases was the same for patients 
treated with radical mastectomy or BCS + RT, although recurrence of tumor in the same 
breast was higher for patients treated with BCS + RT. 11 However, despite the slightly 
higher risk of local recurrence, BCS + R T is still the preferred treatment for women with 
early-stage breast cancer because 20-year overall survival was equivalent for both sets of 
patients. 
Recently, whole breast radiotherapy (WBRT) has been used in conjunction with 
BCS in patients with cancer that has spread to the regional nodes. The combination of 
BCS +lymph node removal+ WBRT, which includes irradiation of the regional lymph 
node area, has been shown to reduce the risk of cancer recurrence in patients with one to 
three positive lymph nodes. 12 However, despite the decrease in local recurrence, 
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extensive use of RT is associated with complications and morbidities including: the 
development of sarcomas (particularly in the chest wall), bone and skin necrosis, poor 
wound healing and infections. In addition, R T is contraindicated for some subsets of 
patients, including those with certain diseases, such as scleroderma, and those who have 
had previous RT. 13 
Furthermore, while the addition of RT to any form of surgery (e.g. total 
mastectomy, simple mastectomy, or BCS) has decreased the 10-year risk of local 
recurrence, nearly 10% of all of patients will still develop recurrence (Table 1.3). In an 
effort to address this problem, new regimens are adding systemic therapy to the standard 
BCS + RT. In multiple clinical trials, results have demonstrated that, for patients with 
node-negative estrogen receptor positive (ER+) breast cancer, ipsilateral local recurrence 
is significantly lower if tamoxifen (TAM) is administered with BCS+RT (4.7% with 
TAM vs. 14.2% without TAM)!4- 17 However, discrepancies still remain regarding 
whether the addition of traditional cytotoxic (i.e. non-hormonal) chemotherapy to TAM 
(i.e., BCS + RT +TAM+ chemotherapy) reduces the risk of recurrence after BCS. 18-19 
Furthermore, no clear trend has been determined correlating the order of administration 
of R T and systemic therapy with a reduced risk of recurrence. 20-22 
Remarkably, while the BCS + RT combination has become the standard treatment 
for breast cancer, with published guidelines clearly describing how physicians should 
administer the thearpy,23-26 notable discrepancies remain regarding the use of RT. 
Despite the unanimous agreement among multiple clinical trials that BCS without RT 
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correlates with higher rates of tumor recurrence,27-31 the number of patients who receive 
BCS + RT or RT following a simple mastectomy has decreased in recent years.32-33 This 
trend is alarming given the clear correlation between the omission of R T and the 
increased likelihood oftumor recurrence following surgical resection of breast cancer. 
While the exact cause of this trend is unclear, the pattern has been associated with 
significantly reduced QoL for patients who elect for RT,34 the distance the patient must 
1 h h d. th 1. . 35-36 d h . ' . . 37-38 trave to reac t e ra 10 erapy c 1mc, an t e patient s socweconorruc status. 
Consequently, alternative treatment strategies or improvements to the implementation of 
currently available treatment options must be investigated. The use of abbreviated 
courses of radiotherapy (ACRT) is currently being evaluated as a method to facilitate 
treatment for those patients for whom travel and economic considerations affect therapy. 
Hypofractionated regimens of RT, in which larger doses of radiation are given over 
shorter periods of time, have shown similar rates of locoregional recurrence and disease-
free survival as standard BCS + RT,39 making this method a favorable alternative for 
certain patient populations.40 Additionally, the use of brachytherapy, which involves the 
local implantation of a radioactive source at the site of tumor excision, has increased 
dramatically since FDA approval in 2002 and consent for Medicare reimbursement for 
treatment in 2004.41 In 2007, nearly 13% of patients selected brachytherapy for adjuvant 
radiation following lumpectomy. However, recent findings from observational data have 
indicated that this technique may be flawed. Based on a review of data from 130,535 
Medicare claims, brachytherapy was associated with a 2.2-fold increase in incidences of 
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subsequent mastectomies during 5-years of follow-up as compared to WBRT, indicating 
that recurrence and complications are more prevalent following brachytherapy than 
standard WBRT.42 
In addition to the human costs (patient mortality and morbidity), breast cancer 
recurrence represents a significant financial burden to both patients and society. The total 
10-year projected costs for patients who do not develop recurrent breast cancer is 
~$42,000.43 In contrast, the cost for treating patients with local recurrence is ~$62,000. 
This 50% increase represents a significant burden that will be dealt with only once 
improved treatments are available that enable durable destruction of primary tumors. 
However, it would be rash to assume that all new therapies will automatically reduce the 
cost of recurrence. For example, the direct medical cost of brachytherapy, including cost 
of facility and physician fee, is so much higher than most other radiation treatments, that 
brachytherapy effectively costs 2-fold more despite reduced non-medical fees, such as 
time and transportation costs (Table 1.3).44 As new treatments are developed they will 
need to be vetted not only for their clinical efficacy, but concomitantly evaluated for the 
financial practicality. The overall financial burden of breast cancer recurrence is a factor 
that cannot be ignored and is one that may eventually influence decisions regarding 
treatment options. 
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1.4 Mesothelioma 
The development of malignant pleural mesothelioma (MPM) is directly linked to 
asbestos exposure, with an identified source of exposure 20-40 years before diagnosis in 
70-80% of MPM patients.45-47 Unfortunately, there is currently no curative therapy for 
MPM, and the median survival time following diagnosis without intervention is only 4-
12 months.48-51 MPM is characterized by aggressive local extension and poor survival. 
Even in patients with early stage disease that should be cured by surgical resection, the 
f 1 · 1 · l hi h 45-46 52-53 D . . rate o ocoregwna recurrence IS extreme y g . ' esp1te surgical 
debulking/resection, chemotherapy, and/or external radiation, the overall 5-year survival 
rate from this disease remains at only 1 0 to 15%. 46• 54-56 
In an attempt to improve prognosis, multimodality approaches have been used to 
treat localized MPM, including aggressive surgical resection with extrapleural 
pneumonectomy (EPP), in which the lining of the chest wall, lung, pericardium and 
d. hr d 45-46 52 57 D . . 11 'd f 1 1 d' h mp agm are remove . ' ' esp1te removmg a ev1 ence o oca 1sease, t e 
majority of patients succumb to recurrent MPM, with 65-80% of recurrences presenting 
as a locoregional relapse that nearly always includes extension into the peritoneal cavity 
requiring resection of the diaphragm.58 To prevent these MPM recurrences, multi-
modality treatment regimens are used consisting of surgery and/or radiotherapy with cis-
or carboplatin plus paclitaxel, gemcitabine or pemetrexed administered either 
intravenously (IV) or intraperitoneally (IP).52' 54' 59-60 If an MPM patient undergoes 
surgery, two cycles of paclitaxel plus carboplatin are given postoperatively, followed by 
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weekly dosing during radiation therapy and two additional cycles of chemotherapy. The 
addition of radiation and platinum-based chemotherapy can increase survival for patients 
with localized disease to 19-22 months.46' 52' 57 In patients with stage I epithelial MPM 
and sufficient cardiopulmonary reserve, surgery followed by chemo-radiation therapy 
dramatically improved 2- and 5-year survival rates to approximately 74% and 45%, 
respectively, yet morbidity remains high at nearly 50% and locoregional recurrence is 
still seen in over 40% of patients (Table 1.4).59' 61 Thus, despite the development of 
aggressive multi-modality regimens, preventing local tumor recurrence represents a 
significant challenge in the treatment of MPM. 
1.5 Local Recurrence in Other Cancers. 
While the work presented in this dissertation pertains to breast and mesothelioma 
cancers, several other types of cancer present with especially prominent treatment failures 
due to local cancer recurrence, including: lung cancer, colon cancer, and soft tissue 
sarcomas. In this section, we will briefly examine the problem of local recurrence in these 
diseases as the techniques and technologies described in this dissertation may, in the 
future, be applied to them as well. 
1.5.1 Lung Cancer 
Patients diagnosed with early stage non-small cell lung cancer (NSCLC) undergo 
cytoreductive surgery as the preferred treatment modality as it has been shown to have 
the best outcome. However, the risk of local recurrence is high and only 20% of NSCLC 
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patients are suitable for the procedure. Smaller resections (e.g., wedge resection vs. 
lobectomy) result in increased local and nodal recurrence but are often necessary due to 
the need to preserve patient lung function. Thus, one goal of lung cancer treatment has 
been to decrease the size of the resection while still avoiding local/regional recurrence. 
While several studies with large numbers of participants have demonstrated that 
cisplatin-based chemotherapy decreases the incidence of recurrence and improves the 
overall 5-year survival, the regimen' s toxicity prevents its use in patients with significant 
comorbidities or complications after lung resection. 62-65 Treatment with paclitaxel shows 
modest improvements to overall survival, but the strategy is limited as the response rate 
is generally poorer than with platinum-based agents.66-67 Due to these limited and mixed 
results, chemotherapy is not the standard of care for early stage NSCLC; its benefit is 
unclear, and there is an increased mortality due to the side effects.68-69 
As in the case of breast cancer, discussed above, RT is used to prevent local lung 
cancer recurrence. Postoperative radiation therapy (PORT) was used following resection 
in patient's with early stage lung cancer; however, meta-analyses conducted in 1998 and 
2011 resulted in the contraindication of PORT following a complete tumor resection if 
mediastinal involvement is minimal (pNO and pN1) as PORT is associated with reduced 
survival. 70-71 Furthermore, R T can lead to esophagitis, pneumonitis, and impaired 
postsurgical healing, making this therapy undesirable in these patients who already suffer 
from impaired pulmonary function due to the surgical resection of lung tissue. 72 Despite 
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these dangers, PORT is still being investigated in pN2 patients as this group has a high 
risk of regional recurrence outweighing the potential associated complications. 
Alternatively to PORT, brachytherapy is also used in early state NSCLC 
resections. Multiple studies have shown that brachytherapy can decrease the rate of local 
recurrence following segmental resection to the equivalent of lobectomy in patients who 
cannot tolerate the more invasive surgical procedure.73-77 Localized brachytherapy has 
demonstrated durable and significant benefits to disease-free progression and survival 
with isolated tumors following resection. However, the adoption of brachytherapy has 
been slow due to its cumbersome method of administration, radiation handling issues, 
d 1. . d '1 b'l' 74-75 78-79 p . . 1 bl . h hi hni . 1 d h an 1m1te avm a 11ty. ' nnc1pa pro ems w1t t s tee que me u e: t e 
uncertainty of the resultant dosimetry;75 significant administrative overhead; requirement 
of exposure precautions for health care personnel handling the seeds and patient contact 
for months after treatment; and, limited availability with only 50-60 centers offering this 
. 74-75 treatment opt10n. 
1.5.2 Colorectal Cancer 
For patients diagnosed with colorectal cancer (CRC) limited to the mucosa, 
submucosa, or muscularis propria (i.e., stage 1), the gold standard of treatment is surgery, 
as the overall 5-year survival for these patients is >85%, and the risk of recurrence is 
quite low.80 However, patients presenting with more advanced but node negative (i.e. 
stage II, ~ 114 of all patients) or node positive (i.e. stage III, ~ 113 of all patients) tumors 
have a significantly higher risk of recurrence following surgical resection without 
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adjuvant therapy and corresponding 5-year recurrence rates of approximately 25% and 
50%, respectively. 81 -82 About half of local colorectal recurrences occur directly at the 
anastomosis or resected tumor bed, with more than 50% of patients having no metastases 
at the time of local recurrence. Once the tumor recurs, the overall 5-year survival rate for 
patients with localized disease drops dramatically to only 28%.83 
Due to the high risk of recurrence for patients presenting with stage III tumors, 
adjuvant chemotherapy, particularly 5-fluorouracil (FU)-based treatment, is routinely 
used as it has been shown to improve the overall 5-year survival by 10-13%.84-86 For 
patients with stage II CRC, adjuvant chemotherapy is indicated only for those with 
inadequately sampled nodes, T4 lesions, perforation, or poorly differentiated histology.80' 
87-88 
Unlike chemotherapy, the use of RT as an adjuvant therapy for colorectal cancer 
is limited. Currently, radiation therapy has no standard role in the management of patients 
with colon cancer. 89 Brachytherapy is reserved for those unfit or unwilling to undergo 
surgery and almost exclusively used for select rectal cancer patients.90 
1. 5. 3 Sarcoma 
Loco-regional recurrence remams a clinically significant problem in the 
management of soft tissue sarcomas, particularly for those arising in the abdomen, pelvis, 
and retroperitoneum (which account for approximately 40% of all sarcomas).91 In 
particular, the large size and anatomic complexity of sarcomas at these sites at diagnosis 
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typically results in positive microscopic margins after a macroscopically complete 
resection. Thus, loco-regional recurrence is a common pattern of failure, with 5-year 
recurrence rates of 50% or greater.92-95 The 5-year overall survival rates from several 
large retrospective surgical series range from 36% to 63%.92-99 Mortality is generally due 
to the subsequent development of loco-regional, rather than distant, relapse. Thus, 
strategies to improve survival in patients with sarcomas of the abdomen, pelvis, and 
retroperitoneum must reduce the high loco-regional relapse rates. 
The standard of care for sarcomas at these sites remains a radical, 
macroscopically complete resection with satisfactory surgical margins (often requiring 
bl . f d' . b f b . . ) 98 100-102 en- oc resection o a Jacent viscera ecause o tumor a utment or mvas10n . ' 
However, the anatomic variability of these tumors makes standardized microscopic 
margin assessment, as might be performed for smaller tumors of visceral origin (e.g., 
breast or rectal carcinomas), challenging. Given these limitations, virtually all patients are 
considered to be at risk for loco-regional relapse, irrespective of reported microscopic 
margin status. Furthermore, when surgical excision is performed on recurrent tumor, the 
risk of subsequent recurrence is approximately equal to that for the primary tumor. 103 
Adjuvant therapy of any form (e.g., RT or chemotherapy) is not routinely 
provided outside of the context of clinical trials as these additional treatments have 
limited benefit. Single institution studies have demonstrated the safety and feasibility of 
delivering perioperative external beam RT with or without intraoperative RT, 
combination chemo-RT, or single-dose hyperthermic intraperitoneal chemotherapy with 
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acceptable treatment-related toxicity. However, attempts to evaluate the superiority of 
any combined-modality treatment in multi-institutional trials have generally been either 
. 1 . ~ .1 d d 1104-106 s· d. . mconc us1ve or 1a1 e ue to poor accrua. mce no a JUVant strategy consistently 
reduces loco-regional recurrence rates for sarcoma, novel alternative treatments are 
needed. 
1.6 Summary 
Local tumor recurrence following surgical resection of primary solid tumors is 
under-addressed in the field of cancer therapy and research. A significant proportion of 
patients who present with early-stage disease that should be curable with resection and/or 
adjuvant therapy will nevertheless develop local recurrence. Current adjuvant radio- and 
chemotherapy strategies designed to reduce local recurrence have shown modest 
improvements in some types of cancer but are inevitably hampered by off-target side 
effects and an inability to completely destroy all remaining tumor. Future research to 
improve these therapies will likely aim to achieve more specific, localized, or targeted 
delivery of therapy (radio-, chemo-, or hormonal) using novel drug delivery systems and 
methods of administration-. 
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Total Cases Stage at Diagnosis 5-year Relative Survival 
Diagnoses Deaths Localized Regional Distant Localized Regional Distant 
Breast Cancer 230,480 39,520 60% 33% 5% 99% 84% 23% 
Table 1.1. Predicted breast cancer diagnoses and deaths as well as the stage distribution 
and 5-year relative survival at diagnosis for 2001-2007. 1' 107 
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Type Treatment 1 0-year Risk. of Recurrence OS (10 yrs) 
All•s Any breast surgery 27.2% (LR) 54.5% 
Any breast surgery + RT 8.8% (LR) 56.6% 
Node-negative47 RM 8.0% (LR + RR) 25.1% (DR) 60 .2% 
TM 12.3% (LR + RR) 26.3% (DR) 61.4% 
TM + RT 4.8% (LR + RR) 28.1% (DR) 57.3% 
Node-positive 12 RM 15.1% (LR + RR) 39.0% (DR) 41.1% 
TM + RT 13.6% (LR+ RR) 41.2% (DR) 39 .1% 
DCIS12 BCS 22-54% (LR) N/A 
BCS + RT 9-28% (LR) 
Node-negative48 BCS 31 .0% (LR +DR) 87.3% 
BCS + RT 15.6% (LR + DR) 89 .1% 
Node-positive29 BCS 63.7% (LR + DR) 57 .4% 
BCS + RT 42.5% (LR + DR) 65.8% 
Node-negative, BCS + RT 14.2 (LR + RR) 76% 
ER-positive29 BCS + RT + TAM 4.7 (LR +RR) 80% 
Node-negative49 RT 6.7% (LR) 84 .4% 
HRT 6.2% (LR) 84.6% 
DCIS, ductal carcinoma in situ; RT, radiotherapy; RR, regional recurrence; LR, local recurrence; TM, 
total mastectomy; RM, radical mastectomy; DR, distal recurrence; BCS, breast-conserving surgery; 
ER, estrogen receptor; OS, overall survival; HRT, hypofractionated regimen; TAM, tamoxifen 
Table 1.2 Breast cancer risk of recurrence and overall survival as a function of treatment 
regimen. 
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Cost Whole Brest Partial Breast 
WBRT WBRT-B WBRT-AC WBRT-IMRT APBI-IC APBI-IT APBI-30- APBI-IMRT 
($) ($) ($) ($) ($) ($) CRT($) ($) 
Payer's 
Technical 5,800 7,500 4,100 15,600 15,800 13,000 5,000 7 ,100 
Professional 1,600 2,000 1,300 2,300 2,000 3,800 2,200 2 ,100 
Subtotal 7,400 9,500 5,400 17,800 17,800 16,800 7,200 9,200 
Patient's 
Time 700 900 500 900 300 300 300 300 
Transport 400 500 200 500 200 200 200 200 
Subtotal 1,100 1,400 700 1,400 500 500 500 500 
Society's Total 8,500 10,900 6,100 19,300 18,300 17,300 7,700 9,700 
WBRT, whole breast radiotherapy; WBRT-B, whole breast rad iotherapy with boost; WBRT-AC, whole breast radiotherapy using 
hypfractionated accelerated schedule; WBRT-IMRT, intensity modulated whole breast radiotherapy; APBI-IC, partial breast high 
dose rate brachytherapy; APBI-IT, partial breast interstitial brachytherapy; APBI-30-CRT, partial breast 3D conformal 
radiotherapy; APBI-IMRT, intensity modulated partial breast radiotherapy. 
Table 1.3 Summary oftotal direct costs of radiation therapy (RT) for breast cancer (eight 
. )44 treatment regimens 
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Recurrence 
Treatment {%) 
Local Distant 
EPP 65-80 
EPP + RT 13 64 
EPP + RT + Chemotherapy - - 53 --
*Stage I or II patients only 
Median overall survival 5-year overall survival 
{months) {%) 
19 
10-33.8* 
23-51 
15 
-50* 
Table 1.4 Local recurrence and survival statistics for patients with malignant pleural 
mesothelioma receiving extrapleural pneumonectomy (EPP) or EPP plus radiation 
therapy or chemotherapy. 
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CHAPTER 2: Microscopy and Tunable Resistive Pulse Sensing Characterization of 
the Swelling of pH-Responsive, Polymeric Expansile nanoparticles 
2.1 Chapter Forward 
This chapter we describe the characterization of eNP swelling as a function of 
both pH and time using a number of different modalities and techniques. Prior to this 
work, our published evidence of eNP swelling was limited to dynamic light scattering 
(DLS) measurements in the 2009 JACS108 and 2011 Biomaterial/09 papers and a single 
scanning electron micrograph (SEM) image in the 2012 Molecular Pharmaceutics 
paper. 110 One of the great drawbacks to using DLS is its inability to provide accurate 
sizing measurements for polydisperse samples. This issue was succinctly stated by our 
co-authors in a book chapter from Selected Topics in Nanomedicine:II 1 "Polydispersity, 
aggregation and the presence of large contaminants are key limitations for DLS 
hni 112-113 I th R 1 . h . . h . . f d 1· h tee ques. n e ay e1g approx1mat10n, t e mtens1ty o scattere 1g t is 
proportional to r 6 , where r is the particle radius, so that (for example) the intensity of 
scattered light produced by one 400 nm particle is matched by the light from 64 similar 
200 nm particles. Data relating to an underlying distribution of small particles can be 
swamped or skewed by light scattered from a comparatively low concentration of large 
particles." Thus, using DLS to accurately size eNPs as they swell (with variability in 
initial diameter, swelling rate and fmal degree) is, at best, a challenging proposition. 
Furthermore, the preparation involved in SEM imaging (i.e. , sample drying, Au/Pd 
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sputter coating, use of a vacuum chamber for imaging) and the inability to observe more 
than a small field of view at any one time make this a useful, but somewhat limited 
technique for characterizing particle swelling. 
Thus, in this paper we used several other techniques including light microscopy, 
transmission electron microscopy (TEM), and tunable resistive pulse sensing (i.e. , 
qNano) to investigate eNP swelling. This paper provided an opportunity to: 1) describe in 
detail the effects of varying the parameters of the eNP synthesis procedure on particle 
diameter; 2) elucidate the phenomenon that, regardless of synthesis parameters, the 
majority of particles are 20-50 nm in diameter, as opposed to 100-200 nm as previously 
thought; and, 3) learn to use the qNano (a challenging task particularly at that early stage 
of its introduction to the marketplace) and apply its tunable resistive pulse sensing 
measurements to both determine the concentration of eNPs in their pre- and post-swollen 
states and to probe the deformability of swollen eNPs. The qNano work was made 
possible by the helpful efforts of Sam Yu, Rebecca Warr, Will Anderson, James "Elf' 
Eldridge, Geoff Willmott, and Robert Vogel who donated significant amounts of time to 
training me on the instrument and discussing results. This work was published in 
Nanoscale in 2013 and appears below, as printed, with sections numbered and formatted 
to fit the current document. 
2.2 Introduction 
Nanoparticles (NPs) are extensively investigated as a means to increase drug 
solubility, alter biodistribution, target specific sites within the body, and minimize drug 
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side effects. 114"127 Of the various particle formulations, polymer-based systems offer a 
number of advantages such as biocompatibility, biodegradability, ease of preparation and 
availability: PLGA nanoparticles are one the most widely used polymer particle systems 
because they are readily prepared, and this specific copolymer of lactic and glycolic acid 
is used in current medical products. However, recent studies have reported that the 
control of drug release from PLGA NPs is limited, as this system delivers a significant 
portion of its pay load extracellularly, lacks a triggering or responsive property to 
concentrate its payload at a specific site, and, often requires incorporation of a ligand to 
achieve cellular targeting. 128 Even with these limitations, PLGA NPs have demonstrated 
some success in a number of in vivo studies. 129 Nonetheless, significant research efforts 
are focused on many areas in order to achieve better overall NP performance, including 
the development of NPs that respond to external (e.g., light) or internal biological (e.g. 
130-1 32 
pH or oxidative stress) cues. 
Responsive NP systems can be synthesized from a variety of materials, each 
• · · c. • 1· h 131 - 132 F ' 2 1 1· 1 b d 1mpartmg a umque 1unct10na 1ty to t e system. 1g. . out mes severa roa 
categories of stimuli, such as pH, temperature, light, oxidation/reduction, or osmolality 
increases/decreases, that may be used to trigger various NP responses, such as 
degradation, swelling/ shrinking, particle inversion/ shape change, or 
hydrophobic/hydrophilic structural changes. Recent examples of such responsive systems 
include pH-responsive polyacids, such as poly(acrylic acid) (PAAc), or polybases, such 
as poly(N,N- dimethyl aminoethyl methacrylate) (PDMAEMA), that are protonated or 
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de-protonated depending on local pH with the resulting ionic interactions frequently 
1 . . 11. 11 f h . 1 123 133-134 h resu tmg m net swe mg or co apse o t e matena. ' T e pH-profile and 
hydrophobic/hydrophilic characteristics of these polymers can be tuned by selection of 
h . . 135 N · l t e appropnate monomer uruts. umerous temperature responsive po ymers stem from 
the poly(N-isopropylacrylamide) (PNIPAAm) family of materials having lower critical 
solution temperatures (LCSTs) in the physiological range (32-42 °C) at which the 
· l · l . . 133-134 Ph . matena expenences a net vo ume contractiOn or expanswn. otoresponsi ve 
particles are obtained by introducing photo-chromic molecules, such as azobenzene, 
which can undergo cis-trans isomerization. 133 Reactive oxygen species, which are 
generally up-regulated in pathologic tissues and are found in cell lysosomes, may also 
trigger conformational, hydrophobic/hydrophilic or size/shape changes. 136-138 Enzymatic 
cleavage (e.g. lysosomal glutathione cleavage of disulfide bonds)136 also represents a 
nl d . 134 commo y use trigger. 
Of these many triggers, pH-responsive materials are frequently selected for 
applications involving delivery to tumors or sites of inflammation due to the lower pH 
fil b. . . h . t36 139-140 S l H · NP d 1. pro I e u Iqmtous m t ese tissues. ' evera p -responsive e Ivery systems 
have been developed. Among others, Murthy and collaborators have used pH-responsive 
polymeric particles to increase the uptake and endosomal release of oligonucleotides in 
hepatic cells. 141 Jabr-Milane and coworkers used poly(b-arnino esters) (PbAE), which 
are hydrophobic at physiologic pH but rapidly dissolve at pH < 6.5 (i.e., pH found in 
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tumor microenvironments and endosomes), to achieve intracellular delivery of 
paclitaxel. 142 Frechet and coworkers synthesized pH-responsive NPs from acetylated 
d I d 1. c- . 143-146 Al . . 1 h .1. d extran po ymers as e Ivery agents 10r vaccmes. mutam et a . ave uti 1ze dual 
pH-/oxidative-stress responsive particles to modulate intracellular burst release of 
drugs. 138 These examples illustrate several applications of pH-responsive NPs. For an in 
depth review, we refer the reader to reviews by Ganta et al. 136 (2008), Motomov et al. 134 
(2010), and Colson and Grinstaff130 (2012). 
Our interest is in responsive polymeric NPs that respond to a pH-trigger in order 
to deliver drug intracellularly. However, instead of relying on particle degradation or 
dissolution to achieve drug release, we utilize particle swelling. Due to their pH-induced 
expansion at mildly acidic conditions, such as those found within the cellular endosome, 
we refer to these particles as "expansile nanoparticles" or eNPs. The mechanism of action 
of these particles is outlined in Fig. 2.2. The motivation for the studies described herein 
stems from recently published results demonstrating that eNPs, when loaded with the 
chemotherapeutic agent paclitaxel (Pax), are superior to traditional methods of Pax 
delivery using Cremophor/ethanol (Pax-C/E) (or non-expansile particles) in several in 
vivo models. Specifically, paclitaxel-loaded expansile nanoparticles (Pax-eNPs) are 
efficacious in murine models of Lewis Lung Carcinoma, breast carcinoma, and human 
1. . 1 h 1. 109 147-149 Th b.l. f p NP rna 1gnant pentonea mesot e wma. ' e a 1 1ty o ax-e s to prevent tumor 
establishment and/or delay tumor recurrence is hypothesized to be a consequence of: (1) 
local delivery to the site of the primary cancer and uptake by the tumor; 109 (2) lymphatic 
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trafficking of the eNPs and delivery of Pax to lymph nodes; 147' 150 and (3) the expansion 
of the eNP following cellular uptake and its resulting ability to act as an intracellular 
depot for Pax. 110 Given the importance of eNP composition, reactivity, and resulting 
swelling for its in vivo performance, we now investigate these characteristics by studying 
the size, structure, and morphology of eNPs in the condensed and expanded state. We use 
a combination of traditional particle characterization modalities such as scanning electron 
microscopy (SEM), conventional transmission electron microscopy (TEM), freeze-
fracture transmission electron microscopy (ff-TEM) and fluorescence microscopy, as 
well as a new nanopore-based characterization technology, the qNano, which measures 
both individual particle size as well as overall particle concentration in situ using tunable 
resistive pulse sensing. 
2.3 Results and Discussion 
2. 3.1 Expansile Nanoparticle Synthesis and Control of Particle Size 
Expansile nanoparticle monomer and crosslinker were prepared according to a 
previously reported method108 with slight modifications to improve yield and purity (see 
Fig. 2.2 and Fig. 2.16). In brief, 2,4,6-trimethoxybenzaldehyde and 1,1, 1-
tris(hydroxymethyl)ethane were reacted in the presence of a catalytic amount of H2S04 to 
produce an intermediate, (5-methyl-2-(2,4,6- trimethoxyphenyl)-1 ,3-dioxan-5-
yl)methanol, which was further reacted with methacryloyl chloride in the presence of 
triethylamine (TEA) to produce the monomer unit, (5-methyl-2-(2,4,6-
trimethoxypheny 1 )-1 ,3 -dioxan-5-y l)methy 1 methacrylate. The crosslinker, 1 ,4-pheny lene 
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bis(2-methylacrylate), was synthesized by reacting hydroquinone with methacryloyl 
chloride in the presence of TEA. 
Nanoparticles were prepared usmg a mini-emulsion oil-in-water suspension 
created via sonication followed by polymerization of the acrylic monomer and 
crosslinker in the presence of a free radical initiator (Fig. 2.3). Three different 
polymerization reactions were investigated including: tetramethylethylenediamine 
(TEMED) with ammonium peroxydisulfate (APS), azobisisobutyronitrile (AIBN) in the 
presence of heat, and eosin Y with 1-vinyl-2-pyrrolidinone under exposure to unfiltered 
light from a xenon arc lamp. Due to ease of use and consistency of particle 
polymerization, the TEMED/ APS method was used to prepare eNPs for all of the 
subsequent nanoparticle characterization studies. 
Nanoparticle size is controlled by adjusting the amount of surfactant, in this case 
sodium dodecyl sulfate (SDS), in the aqueous phase as well as the amount of sonication 
energy used to form the mini-emulsion (Fig. 2.3). Dynamic light scattering (DLS) results 
show that the average size of eNPs depends logarithmically (R2 = 0.99) on the ratio of 
surfactant to monomer with higher ratios of SDS: monomer leading to smaller particles 
(size range 20-300 nm) (Fig. 2.17, left). Similarly, eNP size also depends logarithmically 
(R2 = 0.95) on the sonication energy used to create the mini-emulsion with higher 
sonication energies leading to smaller particles (size range 150-900 nm) (Fig. 2.17, 
right). 
In order to confirm the size measurements obtained via DLS, we performed 
scanning electron microscopy (SEM) on the NP suspensions. In all cases, SEM images 
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revealed polydisperse size distributions with the largest population of particles (by 
number) between 20-50 run (Fig. 2.4, top). By filtering the particles with a 0.22 mm 
filter, the smaller population of particles was isolated from the larger population (Fig. 2.4, 
bottom). The discrepancy in particle size measured using DLS and SEM can be explained 
by DLS's bias toward disproportionately weighting the size of larger particles. 113 
2.3.2 Expansile Nanoparticle Swelling 
Previously published characterizations of eNP swelling using DLS demonstrate 
an ~ 1 OX increase in eNP diameter after 1 d of exposure to pH 5. 108 Particle swelling 
closely follows the hydrolysis ofthe pH-labile protecting group (Fig. 2.2), and release of 
Pax from the eNP is triggered by particle swelling at pH 5. 108 To further characterize the 
differences in size and morphology of eNPs in the unswollen vs. swollen state, we used a 
variety of techniques including scanning electron microscopy, conventional transmission 
electron microscopy, freeze-fracture transmission electron microscopy, fluorescence 
microscopy, and tunable resistive pulse sensing. Cumulatively, these characterization 
modalities allow interrogation of particle s1ze and morphology both in aqueous 
suspension and in dried or lyophilized form. 
2. 3. 2.1 Electron Microscopy 
Expansile nanoparticles maintained at pH 5.0 or pH 7.4 for up to 3 d were 
examined using SEM (Fig. 2.5). Particles maintained at neutral pH ranged from 20-200 
run in diameter whereas those exposed to acidic pH 5.0 increase in diameter with sizes 
ranging from 200 run to 2 ~m, or more. In addition to SEM, freeze-fracture transmission 
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electron microscopy (ff-TEM) was used to examme the nanoparticles. ff-TEM was 
chosen because it allows preservation and replication of the state of the particle in 
solution. Expansile nanoparticles maintained at pH 7.4 appeared as spherical 50-200 nm 
structures, while eNPs maintained at pH 5.0 appeared as larger irregular structures 
approximately 1 ~-tm in diameter (Fig. 2.6). In the pH 5.0 samples, a distinct lack of 
smaller 50-200 nm structures was observed. 
Lastly, we employed conventional transmission electron microscopy (TEM) to 
visualize eNPs labeled with a covalently bound iodine co-monomer. The results revealed 
that, following 3 d at pH 5.0, eNPs swell into a heterogeneous population of particles 
spanning a wide range of swollen or semi-swollen states and, as before, controls 
maintained at pH 7.4 show no significant changes (Fig. 2.7). Of particular note are four 
broadly defined phases of swelling observed in the "swollen" population of eNPs 
outlined in Fig. 2.7, including, from least to most swollen: (1) particles showing little or 
no swelling; (2) particles with an unswollen core and an expanding corona that accounts 
for s50% of the particle diameter; (3) particles with a small unswollen core and large 
swollen corona ::::50% of the particle diameter; and, (4) particles that have swollen so far 
they lack a solid core and exhibit a diminishing overall diameter, which we hypothesize 
occurs as the ester crosslinks are cleaved and polymer chains diffuse away. It is expected 
that, eventually, all particles will swell to this fourth state. The morphology and ringed 
structure of the unswollen-core-swollen-shell (or corona) eNPs seen in Fig. 2.7 is 
reminiscent of core-shell nanoparticles imaged with TEM, such as gold-core silica-shell 
nanoparticles, platinum-maghemite core-shell nanoparticles, and nanocapsules 
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synthesized by Chen, Teng, Wang, and Liz-Marzan, respectively. 151 -154 These results 
demonstrate that eNP swelling is a continuous, prolonged, process which, due to particle-
to-particle heterogeneity, results in a broad distribution of particle features, morphologies 
and sizes at any single time point. 
2. 3. 2. 2 Fluorescence Microscopy 
In order to optically observe and characterize individual eNPs, we prepared larger 
particles of ~450 nm in diameter doped with a fluorescent, covalently incorporated, 
rhodamine co-monomer. Particle diameters were measured after 20 hours using post-
acquisition size calibration in Image J. Results showed eNPs held at neutral pH 7.4 have 
an average diameter of 479 ± 257 nm. In contrast, eNPs maintained at acidic pH 5.0 for 
20 hr are significantly (P < 0.001) larger with an average diameter of 1556 ± 1274 nm 
and a distribution of diameters ranging from several hundred to several thousand 
nanometers (Fig. 2.8). Similarly to the TEM data above, these results once again 
reinforce the heterogeneous nature of eNP swelling, wherein particles swell to various 
degrees and at different absolute rates. 
It is of note that the swollen structures observed in both ff-TEM (Fig. 2.6) and 
fluorescence microscopy studies (Fig. 2.8, insert) have a similar, characteristic 
irregularity to their surface features. This ruffled appearance was not observed using 
SEM; rather, the swollen particles appeared smooth and spherical. It is possible that the 
vacuum drying/sputter coating process required for SEM preparation smoothed over and 
homogenized the particle surface. These data illustrate the need for using multiple 
modalities when investigating NP features and morphology. 
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2.3.2.3 qNano: Two Point Swelling Measurement 
Having studied the morphological changes in eNPs as they swell with time, we 
next quantified the overall population dynamics of eNP swelling, and, specifically, 
further probed the heterogeneity of swelling observed using TEM and fluorescence 
microscopy regarding absolute size and rate of swelling. For these studies, we used a 
qNano, which utilizes a tunable resistive pulse sensing technique to characterize particles. 
Specifically, this technology uses a single, tunable nanopore cut into an elastomeric 
b . d . . 1 . 1 b . 1 b . 155-159 mem rane to size nano- an microparttc es on a partie e- y-parttc e asis. The 
lower limit of size detection on the qNano is ~ 70 nm while the upper limit is tens of 
microns. Relative size is determined in an aqueous environment by measuring the 
decrease in electrical current passing through the nanopore as particles obstruct the pore 
during translocation from one side to the other. Absolute size is determined by comparing 
the magnitude of the decrease in electrical current of an unknown particle and a known, 
standard calibration particle at the same running conditions (i.e., pore type, stretch, 
electrolyte, pressure, and applied voltage). 
To determine concentration, an unknown sample is measured at several different 
externally applied pressures, each of which produces different rates of particle 
translocation through the pore-greater applied pressures result in nano- particles passing 
through the pore faster and thus higher translocation rates. A standard particle is similarly 
measured at multiple applied pressures using the same running conditions. A linear plot 
of pressure vs. translocation rate is then constructed for each sample. Particle 
concentration is directly related to the slope of the pressure vs. translocation rate graph 
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and, by taking the ratios of the slopes of the known and unknown samples, the 
concentration of the standard is used to determine the concentration of the unknown 
156 
sample. 
Pilot studies to investigate eNP swelling by qNano demonstrated results 
consistent with electron and fluorescence microscopy experiments. Expansile 
nanoparticles showed a significant (P < 0.001) change in size between those exposed to 
pH 7.4 (98 ±51 nm) and those exposed to pH 5.0 (673 ± 461 nm) for 3d (Fig. 2.9). 
2.3.2.4 qNano: Time Course Swelling Measurement 
Each qNano nanopore has a dynamic range over which its performance is 
optimal. If it is stretched too little, the pore will not open to fill with electrolyte and allow 
translocation of particles. If stretched too far, the pore will tear and become unusable. 
Table 1 gives the available pores and their optimal dynamic ranges. 160 In practice, the 
dynamic range for larger pores is greater than the values given in Table 1; i.e. , an NP800 
can be stretched wide enough to measure 2000 nm particles without causing damage. 
However, due to the limits of the dynamic range on any given pore, it is impossible to 
measure the size of both small (100-200 nm) and large (500-2000 nm) particles 
simultaneously. The qNano measurements of eNP swelling in Fig. 2.9 were performed 
using a single NP400 nanopore. It was, therefore, possible that unswollen particles 
smaller than 200 nm were present in the pH 5.0 population but were not being detected. 
To address this concern, as well as to investigate the time course evolution of eNP 
swelling with a focus on particle subpopulations, we performed a further investigation. 
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Slightly larger particles (250 nm), which are more easily measured on the qNano, were 
exposed to acidic and neutral conditions as before and the diameter measured by qNano 
at time 0 and at subsequent time points after 3 d and 5 d of swelling. At each time point, 
particle size was measured on both a small (NP400) and large (NP800) nanopore 
(combined dynamic range 200-2000 nm) to ensure neither large nor small particles were 
excluded from the measurement. Additionally, particle concentration was determined at 
each time point and on each nanopore using a previously published technique described 
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m t e prevwus sectwn. 
Expansile nanoparticles showed an overall increase in diameter upon exposure to 
pH 5.0 (Fig. 2.10) from an average diameter of221 ± 36 nm to 418 ± 112 nm and 1230 ± 
469 nm on day 0, 3, and 5, respectively (Fig. 2.10 and Fig. 2.18). No change in size was 
observed at neutral pH 7.4 (data not shown). Furthermore, the initial eNP concentration 
was 8.5 x 1011 particles per mL and this decreased to 2.3 x 1011 and 3.9 x 1011 particles 
per mL on day 3 and day 5, respectively (Fig. 2.11, right). This decrease in overall 
particle concentration may be indicative of eNP degradation following swelling, as noted 
in previous sections. By measuring both small and large particles separately, on suitable 
pores, at each time point, it was confirmed that particle swelling occurs heterogeneously 
within the eNP population. The percent of particles measured on the small pore, as 
determined by particle concentration, decreased with time from >99% to 72% to 10% at 
0, 3, and 5 d, respectively, while the average diameter measured on this pore did not 
change significantly (215 ± 35 nm, 240 ± 55 nm, and 246 ± 40 nm, respectively). 
Concurrently, the percent of particles measured on the large pore increased from <1% to 
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28% to 90% at 0, 3, and 5 d, respectively, with the average diameter increasing 
significantly (P < 0.0001) from 876 ± 259 nm to 1339 ± 516 nm from day 3 to 5 (Fig. 
2.11, left) . 
2.3.2.5 qNano: Deformation ofSwollen eNPs 
The data presented thus far demonstrate that eNP swelling is a continuous process 
wherein the particle transforms from a condensed, hydrophobic particle into a swollen, 
more hydrophilic, hydrogel-like structure. We therefore hypothesized that, in the swollen 
state, the eNP may become soft and deformable with the mass of polymer that is in a 
~100 nm diameter structure now spread throughout a ~1000 nm diameter structure. To 
test this hypothesis, we used the dynamic tunability of the qNano pores. 
Fig. 2.12 and 2.13 illustrate the premise behind this study. Particles, either 
swollen or unswollen, will not translocate the pore if the pore is much smaller than the 
diameter of the particle; in these cases a flat current trace is observed. In contrast, when 
the pore is opened to a size larger than the eNP, either swollen or unswollen, the particle 
will translocate the pore resulting in a single, narrow downward spike in the basal 
current. For swollen eNPs, if the pore is decreased to approximately the same diameter as 
the particle, the eNP can be squeezed through the pore. Due to the interaction between 
the particle and pore, the translocation occurs more slowly, resulting in a broadened 
downward peak in the basal current. This intermediate behavior is not observable for 
unswollen eNPs thus confirming that the peak broadening is due to the softened, 
hydrogel-like state of the water swollen eNP. A representative signal trace from eNPs at 
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pH 5.0 that are either "squeezed" through a small pore or allowed to pass cleanly through 
a large pore (broad vs. narrow translocation peaks, respectively) is given in Fig. 2.13. 
To quantify the difference between these translocation behaviors, we measured 
the full-width half-maximum (FWHM) translocation duration (TD) for unswollen-eNPs, 
swollen-eNPs, and swollen-eNPs squeezed through the nanopore (Fig. 2.14). The mean 
TD for particles at pH 7.4 (0.13 ± 0.17 ms) and un- squeezed eNPs at pH 5.0 (0.15 ± 0.13 
ms) were not significantly different (P = 0.42). However, the TD of eNPs at pH 5.0 
squeezed through the pore (26.4 ± 47.8 ms) was significantly (P < 0.0001) longer than for 
either of the previous cases. 
It is known that particle TD increases with decreasing pore size due to the 
increased excluded particle volume as well as the decreased velocity of the fluid (and, 
hence, the particle) through the pore. 161 However, this increase in TD is typically no 
greater than 50% of the duration for a 20% change in pore size, 162 and, therefore, another 
mechanism must be responsible for the observed increase of over two orders of 
magnitude in TD. 
Unusual signal traces from resistive pulse sensmg measurements have been 
attributed to multiple phenomena, however the reported observations do not satisfactorily 
explain the current eNP swelling data. For example, Willmott et al. used magnetic fields 
to cause aggregation and increased translocation rates of super-paramagnetic beads with 
blockades characterized by multiple overlapped peaks and thus overall increased TD. 163 
However, in the current study, the overall particle concentration (and thus translocation 
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rate) decreases with eNP swelling (Fig. 2.11) thus making the likelihood of multiple, 
nearly simultaneous, overlapping translocations negligible. Furthermore, the signal traces 
in Fig. 2.13 resemble a single translocation event rather than multiple superimposed 
translocations observed by Willmott et al. In a different study, Ang and Yung observed 
increased translocation durations due to increased particle aggregate size. 164 However, 
the increase in duration ( ~4x) is significantly less than the increase observed in the 
current study (over two orders of magnitude different). 
Another study by Platt et al. suggests possible confirmation of the proposed 
mechanism of particle squeezing. The authors demonstrate that rod shaped nanoparticles 
have a dramatically increased TD. 165 While swollen eNPs appear generally spherical, as 
seen via SEM, TEM, ff-TEM, and fluorescence microscopy, it is reasonable to suggest 
that squeezing a swollen eNP through a narrow pore elongates it therefore changing its 
aspect ratio to become more rod-like. 
While it is possible that a combination of factors, such as those noted above and 
others (e.g. viscous boundary effects) contribute to the observed trend, it is clear that 
there is both an empirical and a quantitative difference in the way in which swollen eNPs 
translocate the pore. 
2.3.3 Hydrophobicity ofeNPs as a Function of Particle Swelling 
Having characterized the change in eNP diameter and morphology as a function 
of both time and pH, we next investigated the relative hydrophobicity of the eNP interior 
as a function of these variables. Previous studies have shown that the hydrophobic drug 
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paclitaxel (Pax) can be readily loaded into eNPs with an efficiency over 80%. 108 
Additionally, Pax has an affinity for the swollen eNP that causes it to partition into these 
particles in a 4 : 1 ratio over an aqueous environment. 110 These results suggest that, even 
as the eNP becomes more hydrophilic during swelling in a mildly acidic aqueous 
environment, it maintains sufficient hydrophobic character to preferentially sequester 
hydrophobic drugs from aqueous solution. 
To characterize the hydrophobic nature of the eNP interior, we encapsulated 
covalently bound pyrene-a hydrophobic, solvochromatic fluorophore-in the eNPs. 
Four peaks characterize pyrene's fluorescence emission spectrum with the ratio of the 
peak I area to peak III area serving as an indicator of the hydrophobicity of pyrene's 
environment (Fig. 2.19). For example, in an aqueous environment, this ratio is 2.34 ± 
0.11 while in dimethylsulfoxide (DMSO), which is slightly more hydrophobic, it is 2.05 
± 0.01 and inn-hexane, which is significantly more hydrophobic, it is 1.29 ± 0.01 (Fig. 
2.19). Monitoring the hydrophobicity of pyrene-eNPs revealed a significant (P < 0.001) 
increase in hydrophilicity with swelling at pH 5.0 from a ratio of peak I area to peak III 
area of 1.73 ± 0.01 to 1.83 ± 0.02; no significant change was observed at pH 7.4 
(Fig. 2.15). Using a standard curve of pyrene-emission vs. polarity index for various 
solvents (Fig. 2.19), these changes correlate to an increase in hydrophilicity from an 
environment with a polarity similar to dichloromethane (DCM) or toluene to an 
environment with polarity between that of ethyl acetate and acetone. 
This quantification supports our previously proposed method of eNP swelling 
35 
(Fig. 2.2). Specifically, prior to swelling, hydrophobic eNPs form a suspension in water 
and are "immiscible" with their environment, much the same way DCM and water are 
immiscible. As eNPs swell and achieve a more hydrophilic character similar to that of 
acetone, they also become "miscible" with their environment and water infiltrates the 
polymer network forming a hydrogel-like structure. However, even as eNP hydrophilicity 
increases, the fmal character of the particles is still more hydrophobic than the aqueous 
environment at large. This persistent hydrophobicity is likely the origin of the drug-depot 
effect previously noted and published. 110 Specifi~ally, eNPs can act as intracellular 
depots for separately administered hydrophobic drugs and, therein, provide improved and 
sustained release of these drugs over prolonged periods of time. 
2.4 Conclusion 
In summary, we have characterized polymeric nanoparticles that expand at mildly 
acidic conditions using a variety of techniques. We observed a significant change in eNP 
volume (>350X) using SEM, conventional TEM, ff-TEM, fluorescence microscopy, and 
tunable resistive pulse sensing. eNP swelling occurs in a continuous and yet 
heterogeneous manner over several days. Lastly, the hydrophobicity of eNPs changes 
with swelling in accordance with the proposed mechanism of action leading to the drug-
depot effects previously observed. Continued research with eNPs will increase our 
understanding of how this nanomaterial functions in vitro and in vivo. It will also 
advance the development of new materials that significantly improve the local delivery of 
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chemotherapy to sites of tumor with the goals of preventing tumor growth and recurrence 
while minimizing exposure to non-tumor bearing soft tissues. 
2.5 Supporting Information 
2. 5.1 General Procedures and Materials 
All chemicals were purchased from Sigma-Aldrich or Lancaster Synthesis and used 
without further purification unless otherwise stated. All reactions were performed under 
nitrogen atmosphere unless otherwise stated. 
2. 5. 2 Synthesis of (5-methyl-2-(2, 4, 6-trimethoxyphenyl)-1, 3-dioxan-5-yl)methanol 
The synthesis of this precursor compound follows a previously reported method 
with slight modifications to improve yield and purity (Figure 2.16). 108 First, 1,1, 1-
tris(hydroxymethyl)ethane (5.5115 g, 45 .8 mmol, 3.0 equiv.) and 2,4,6-
trimethoxybenzaldehyde (3.0 g, 15.291 mmol, 1.0 equiv.) were dissolved in 150 mL of 
tetrahydrofuran and 46.5 g of 5 A molecular sieves were added as a desiccant. A catalytic 
amount of sulfuric acid was then added and the reaction mixture was shaken overnight at 
room temperature. When the reaction was complete, 6 mL triethylamine was added to 
neutralize the acid, followed by the addition of 100 mL of CH2Cl2. The molecular sieves 
were then removed using vacuum filtration. The solvent was removed via rotary 
evaporation under reduced pressure and the residue was dissolved in 75 mL of CH2Ch. 
This mixture was then washed three times with 100 mM pH 8.0 Tris buffer and dried 
over anhydrous sodium sulfate. The solvent was subsequently removed using rotary 
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evaporation under reduced pressure to give 3.282 g (77%) of (5-methyl-2-(2,4,6-
trimethoxyphenyl)-1 ,3-dioxan-5-yl)methanol as a light yellow solid. 
2.5.3 Synthesis of (5-methyl-2-(2,4,6-trimethoxyphenyl)-1,3-dioxan-5-yl)methyl 
methacrylate 
The precursor, (5-methyl-2-(2,4,6-trimethoxyphenyl)-1 ,3-dioxan-5-yl)methanol 
(1.5 g, 5.028 mmol, 1.0 equiv.), and triethylamine (2.1 mL, 1.527 g, 15.084 mmol, 3.0 
equiv.) were dissolved in 50 mL of CH2Cl2 and chilled to 0 °C. Methacryloyl chloride 
(1.08 mL, 1.157 g, 11.062 mmol, 2.2 equiv.) was then added drop wise to the solution 
while stirring. The reaction mixture was allowed to warm to room temperature while 
stirring overnight. Methanol ( 1 mL) was added to quench the remaining acid chloride. 
The mixture was then washed three times with 100 mM pH 8.0 Tris buffer and dried over 
anhydrous sodium sulfate. The solvent was subsequently removed using rotary 
evaporation under reduced pressure, and the product was purified by silica gel 
chromatography using 8:2 hexanes:ethyl acetate to give 1.547 g (86%) of (5-methyl-2-
(2,4,6-trimethoxyphenyl)-1,3-dioxan-5- yl)methyl methacrylate as a white solid. 
2.5.4 Synthesis of 1,4-phenylene bis(2-methylacrylate) 
Hydroquinone (1.0 g, 9.09 mmol, 1.0 equiv.) and triethylamine (4.68 mL, 3.4 g, 
3.33 mmol, 3.7 equiv.) were dissolved in 75 mL of CH2Ch and chilled to 0 °C. 
Methacryloyl chloride (3.28 mL, 3.52 g, 3.33 mmol, 3.7 equiv.) was then added drop 
wise to the solution while stirring. The reaction mixture was allowed to warm to room 
temperature while stirring overnight. 1 mL methanol was added to quench the remaining 
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acid chloride. The mixture was then washed three times with 1 M NaOH, once with 
brine, and dried over anhydrous sodium sulfate. The solvent was subsequently removed 
using rotary evaporation under reduced pressure, and the product was purified by silica 
gel chromatography using 10:1 hexanes:ethyl acetate to give 2.24 g (100%) of 1,4-
phenylene bis(2-methylacrylate) as a white solid. 
2. 5. 5 Synthesis of 2-(3-acetamido-2, 4, 6-triiodobenzamido)ethyl methacrylate 
The precursor, 3-acetarnido-N-(2-hydroxyethyl)-2,4,6-triiodobenzarnide (0.5 g, 
.833 rnrnol, 1.0 equiv.), and triethylamine (0.348 rnL, 0.253 g, 2.399 rnrnol, 3.0 equiv.) 
were dissolved in 50 rnL of CH2Ch and chilled to 0 °C. Methacryloyl chloride (0.179 
mL, 0.192 g, 1.833 rnrnol, 2.2 equiv.) was then added drop wise to the solution while 
stirring. The reaction mixture was allowed to warm to room temperature while stirring 
overnight. Methanol 1 rnL was added to quench the remaining acid chloride. The mixture 
was washed three times with 100 rnM pH 8.0 Tris buffer and then dried over anhydrous 
sodium sulfate. The solvent was subsequently removed using rotary evaporation under 
reduced pressure, and the product was purified by silica gel chromatography using 8:2 
hexanes:ethyl acetate to gtve 0.315 g (51%) of 2-(3-acetarnido-2 4 6-
, ' 
triiodobenzamido )ethyl methacrylate as a white solid. 
2. 5. 6 Synthesis of Expansile Nanoparticles (eNPs) 
Nanoparticles were prepared using a previously reported method. 108 Briefly, 50 
mg of monomer, (5-methyl-2-(2,4,6-trimethoxyphenyl)-1 ,3-dioxan-5-yl)methyl 
methacrylate, and 0.5 mg of crosslinker, 1,4-phenylene bis(2-methylacrylate), were 
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dissolved in 0.5 mL of CH2Ch. This organic solution was then added to 2 mL of a 10 
mM aqueous buffer solution containing 8 mg sodium dodecyl sulfate (SDS). This 
mixture was sonicated for 10 min (1 s pulses with a 2 s delay) with 20 W of power under 
an argon blanket to create the miniemulsion. When using the photochemical initiation 
method, following sonication, 20 IlL of a 20 mM aqueous eosin Y solution and 4.27 11L 
of a 10% w/w aqueous 1-vinyl-2- pyrrolidinone solution were added to the emulsion. The 
mixture was then exposed to unfiltered light from a xenon arc lamp at 300 W for 20 min 
while stirring to initiate polymerization. Alternatively, when using the base-catalyzed 
reaction, following sonication, 20 JlL of a 200 mM aqueous ammonium persulfate (APS) 
solution and 2 JlL of N,N,N' ,N'- tetramethylethylenediamine (TEMED) were added to 
the emulsion and stirred under an argon blanket for 2 hr. Alternatively, polymerization 
was conducted by adding 0.5 mg (1% wt/wt) azobisisobutyronitrile (AIBN) to the 
mixture prior to sonication and then, following sonication, heating the emulsion at 60 
degrees Celsius for 2 hr. Following polymerization using any of these three methods, the 
suspension was then stirred overnight while open to the atmosphere to allow the 
remaining solvent to evaporate. The resulting polymeric nanoparticles were then dialyzed 
against 5 mM pH 7.4 phosphate buffer over 1 d to remove excess surfactant and salts. 
When synthesizing rhodamine-labeled nanoparticles, 0.1 mg of PolyFluorTM 570 
(methacryloxyethyl tricarbonyl rhodamine B, Polysciences, Inc.) was dissolved in the 
CH2Cl2 along with the monomer and crosslinker before addition of the organic phase to 
the aqueous phase. When synthesizing acrylic pyrene-labeled nanoparticles, 1 mg of 
PolyFluorTM 394 (1-pyrenylmethyl methacrylate, Polysciences, Inc.) was dissolved in 
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the CH2Cb along with the monomer and crosslink:er before addition of the organic phase 
to the aqueous phase. When synthesizing acrylic iodine-labeled nanoparticles, 1 mg of 2-
(3-acetamido-2,4,6-triiodobenzamido)ethyl methacrylate was dissolved in the CH2Cb 
along with the monomer and crosslink:er before addition of the organic phase to the 
aqueous phase. 
2. 5. 7 Dynamic Light Scattering 
A 10 mL aliquot of nanoparticle suspension was diluted in 3.0 mL of de-ionized 
water. The diameter of the nanoparticles was then measured using a Brookhaven 
Instruments, Inc. 90Plus particle-sizing instrument. All measurements were performed in 
triplicate. 
2. 5. 8 Scanning Electron Microscopy 
Scanning electron microscopy (SEM) was performed using a Zeiss SUPRA 55VP 
field emission SEM. Samples were prepared by diluting a small amount of nanoparticle 
suspension 1:100,000 in de-ionized water and then placing a drop of the diluted 
suspension on a silicon wafer. The sample was allowed to air-dry overnight and was then 
affixed to an aluminum sample stub using copper tape. The samples were coated with 5 
nm of Au/Pd prior to imaging and were imaged at an accelerating voltage of 2 kV. 
Particle diameters were calculated from SEM micrographs using NIH ImageJ. 
2. 5. 9 Freeze Fracture Transmission Electron Microscopy 
For freeze-fracture transmission electron microscopy (ff-TEM), samples were 
quenched using a sandwich technique and liquid nitrogen-cooled 'propane. Using this 
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technique a cooling rate of 10,000 Kelvin per second was reached avoiding ice crystal 
formation and artifacts possibly caused by the cryofixation process. The cryo-fixed 
samples were stored in liquid nitrogen for less than 2 hr before processing. The fracturing 
process was carried out in JEOL JED-9000 freeze-etching equipment and the exposed 
fracture planes were shadowed with Pt for 30 sec at an angle of 25-35 degrees and with 
carbon for 35 sec (2kV/ 60-70 rnA, 1x10-5 Torr). The replicas produced this way were 
cleaned with concentrated, fuming HN03 for 1 d followed by repeated agitation with 
fresh chloroform/methanol (1: 1 by vol.) at least 5 times. Replicas cleaned this way were 
imaged using a JEOL 100 ex electron microscope. 
2. 5.10 Transmission Electron Microscopy 
Transmission electron microscopy (TEM) was performed on covalently iodine-
labeled eNPs using a JEOL 100 ex electron microscope. Samples were prepared by 
diluting a small amount of nanoparticle suspension 1:10 in de-ionized water with 1% 
wt/wt sodium dodecyl sulfate. A 5 mL drop of the diluted suspension was then adsorbed 
to a carbon-coated grid that had been made hydrophilic by a 30 s exposure to a glow 
discharge. Excess liquid was removed with filter paper (Whatman # 1) and the samples 
were stained with 0.75% uranyl formate for 30 s. After removing the excess uranyl 
formate with a filter paper, the grids were examined in a JEOL 1200EX Transmission 
electron microscope or a TecnaiG2 Spirit BioTWIN and images were recorded with an 
AMT 2k eeD camera. 
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2. 5.11 Fluorescence Microscopy 
Fluorescence microscopy was used to visualize the swelling of rhodamine-labeled 
eNPs. Covalently tagged rhodamine-eNPs were prepared as described above with an 
average diameter of 450 nm. Nanoparticles were diluted 1:1000 in either 10 mM pH 7.4 
phosphate buffer or 10 mM pH 5.0 acetate buffer; both buffers contained 0.4% TWEEN. 
After allowing the particles to swell for 1 d, particles were viewed for counting and 
diameter determination using an inverted microscope with fluorescence epi-illumination 
from a Coherent Sapphire solid-state 488-nm laser. A 1 OOX/1.40 NA oil immersion 
objective with Semrock long-pass filters was used to eliminate scattered light from the 
laser illumination and an Andor iXon 897 back-illuminated Electron-Multiplying CCD 
camera was used to record the images. Particle diameters were calculated from the SEM 
micrographs using NIH ImageJ. 
2. 5.12 qNano Measurements 
qNano measurements were performed according to standard operating 
procedures. Briefly, a nanopore membrane is placed onto the pins of the qNano and 
stretched to a pin-to-pin width of 47 mm- 49 mm. Electrolyte is then added to the upper 
and lower fluid cell chambers created/separated by the nanopore membrane. The pore is 
cycled three or more times through stretching and un-stretching ( ~49 mm and ~44 mm, 
respectively) to remove hysteresis. Having opened the pore a voltage is applied across the 
membrane to establish a baseline electrical current through the pore. Fluid is then 
removed from the upper cell and replaced by a suspension of unknown particles. The 
diameter of the pore is adjusted until particles (visualized as individual blockades or 
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"spikes" in the current trace) translocate the pore easily. If particles are too large or small 
to be seen on a given nanopore (i.e. they will not fit through the pore or do not cause a 
decrease in basal current greater than the background noise, respectively), a larger or 
smaller pore is substituted. 
The magnitude of individual blockade events is related to the size of particles 
translocating the pore while particle concentration is related to the rate at which particles 
pass through the pore. The relative size and concentration of two different suspensions of 
particles is determined by comparing the peak height (i.e. blockade magnitude) and rate 
of translocation (particles/min). In order to determine absolute particle size of an 
unknown sample, the sample is measured, followed by measurement of a particle 
standard of known size. Comparison of the blockade magnitude between unknown and 
standard particles allows extrapolation of the unknown particles' size. It is essential, for 
the calibration to be correct, that both the standard and unknown sample are measured on 
the same pore, using the same applied voltage, pore stretch, and applied pressure/vacuum. 
Furthermore, using calibration particles similar to the diameter and concentration of the 
unknown sample can facilitate the accuracy and ease of calibration. 
To determine absolute particle concentration, both the unknown and calibration 
particles are measured at several different applied pressures. A linear plot of pressure vs. 
translocation rate is then constructed for each sample. Particle concentration is directly 
related to the slope of this curve. By taking the ratios of the slopes of the pressure vs. 
translocation rate graph for the unknown sand calibration samples, the concentration of 
the calibration sample is used to determine the concentration of the unknown sample. 
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The following sections detail the particle dilutions and operating parameters (pore 
type/size, stretch, electrolyte buffer, applied pressures and voltage) used in qNano 
measurements. All calibrations were performed using NIST certified carboxylated 
polystyrene particles obtained through Izon Ltd. The nanopores and their diameter/stretch 
were chosen because these parameters allowed facile measurement of eNPs (either 
swollen or unswollen) and standards i.e., particles were able to readily translocate the 
pore without blocking, clogging, etc. 
qNano was used to characterize eNP size as a function of swelling time at neutral 
and mildly acidic pH. To measure the size change after three days, eNPs were diluted 
1 : 1 00 in pH 5. 0 acetate buffer ( 10 mM) and pH 7.4 phosphate buffer ( 1 0 mM) on day 0; 
both buffers were modified with NaCl (25 mM) to increase buffer conductivity. After 3d, 
particles maintained at pH 7.4 were further diluted 1: 1000 in pH 7.4 buffer and sized on 
an NP200 nanopore at a stretch of 44 mm with an applied voltage of 0.3 V under 
atmospheric pressure. Particles maintained at pH 5.0 were further diluted in 1:1000 in pH 
5.0 buffer and sized on an NP400 nanopore at a stretch of 46 mm with an applied voltage 
of 0.3 V under atmospheric pressure. 
Time course measurements of eNPs maintained at pH 5.0 and pH 7.4 for 0, 3, and 
5 d were conducted similarly to the above protocols. However, at each time point, 
particle size was measured on both a small NP400 and a large NP800 nanopore to ensure 
screening of the entire population. At each time point, particle size and count rate were 
measured under at least three different applied pressures on each nanopore thereby 
allowing accurate extrapolation of the measured particle concentration according to Izon 
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protocols, and as detailed above. 156 The nanopore stretches, applied voltages, and 
pressures used at each time point and on each nanopore are given in Table 2.2. 
To investigate the deformability of eNPs in their swollen state, eNPs were maintained at 
pH 5.0 and pH 7.4 for 3d as described above. Particles in pH 5.0 buffer were then run on 
an NP800 nanopore at a stretch of 49 mm. Having sized a number of particles in this 
manner, the pore was then dynamically closed down until translocation events were 
observed to significantly increase in duration (pore stretch ranged from ~46 mm - 47 
mm). Particles maintained at pH 7.4 were too small to be measured on an NP 800 
nanopore and were therefore measured on an NP 400 nanopore at a stretch of 4 7 mm. 
Pore size was dynamically closed down to capture any particle behavior similar to that 
seen in eNPs at pH 5.0. 
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Categories of stimuli-responsive nanoparticles: 
Typical stimuli 
- temperature 
- pH 
- oxidation I 
reduction 
- light 
- osmolality 
increase I 
decrease 
Typical nanoparticle responses 
Hydrophobic I hydrophilic 
conformational change 
o-. 
Degradation 
• • •• 
•• 
_. ...... . 
. ,~ .. 
• • • • 
Shrinking I swelling 
Inversion or change of shape 
Figure 2.1 Illustration of commonly employed nanoparticle stimuli and subsequent 
responses. 
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Un-expanded eNP 
diam. -100 nm 
o -:? oo -:? oo -:? I o 
:::,., I :::,., I :::,., 
......_ o......_ o......_ 
hydrophobic nanoparticle polymer 
] 
trimethoxybenzylidene 
acetal protecting groups 
Expanded eNP 
diam. -3-10X 
~~~ 
OH OH OH OH OH OH 
hydrophilic nanoparticle polymer 
Figure 2.2 Schematic showing the mechanism of expansile nanoparticle ( eNP) swelling. 
The NP polymer is hydrophobic under neutral pH ~ 7.4 conditions (left). The 
trimethoxybenzylidene protecting group is cleaved off each polymer repeat unit under 
mildly acidic pH ~5 .0 aqueous conditions leaving behind two alcohol functionalities 
(right). Water infiltrates this more hydrophilic network swelling the particle and resulting 
in an increase in particle size. 
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organic phase: 
monomer 
crosslinker 
1) Emulsification 
2) Polymerization 
I > 
Figure 2.3 Schematic of eNP synthesis: 1) aqueous and organic phases are emulsified 
with a sonication probe to form a suspension of organic droplets in aqueous solution; and, 
2) polymerization of an acrylic monomer and crosslinker produces crosslinked polymer 
nanoparticles. 
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Figure 2.4 Scanning electron micrograph of eNPs before (top) and after (bottom) 
filtration through a 0.22 11m filter following the mini-emulsion polymerization synthesis. 
Prior to filtration, two populations of particles, 20-50 nm and 100-200 nm, are observed 
(top, right); after filtration only the smaller 20-50 nm population remains (bottom, 
right). Scale bars = 500 nm. 
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Figure 2.5 Scanning electron micrograph shows unswollen (left) and swollen (right) 
eNPs following 3d exposure to pH 7.4 and pH 5.0 respectively. 
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Figure 2.6 Freeze-fracture transmission electron micrograph shows unswollen (left) and 
swollen (right) eNPs following 1 d exposure to pH 7.4 and pH 5.0 respectively. 
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pH 7.4 
unswollen 
••• 
little or no-
swelling 
pH 5.0 
core~ 50% 
ofeNP diam. 
core :s; 50% 
ofeNP diam. 
no distinct 
core 
all scale bars 250 nm 
Figure 2.7 Transmission electron micrographs show eNPs after 3 d exposure to pH 7.4 
(left) or pH 5.0 (right). eNPs maintained at pH 7.4 are unswollen, appearing as solid, 
dense, black spheres. eNPs at pH 5.0 conditions swell heterogeneously exhibiting a wide 
variety of swollen states characterized primarily by the appearance and subsequent 
disappearance of an unswollen-core surrounded by a swollen-corona. Three 
representative images (one per row) are shown for each state. Scale bars = 250 nm. 
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Figure 2.8 Histogram showing distribution of eNP sizes measured by fluorescence 
microscopy. Particles maintained for 20.hours at pH 5.0 (red) are significantly larger (P 
< 0.001) than eNPs maintained at pH 7.4 (blue). Photographs (inset) are representative 
images of rhodamine-labeled eNPs at pH 7.4 and pH 5.0. Scale bar= 5 f.Lm. 
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Figure 2.9 Histogram showing the distribution of eNP sizes measured by qNano---eNPs 
maintained for 3 d at pH 5.0 (red) are significantly larger (P < 0.001) than eNPs 
maintained at pH 7.4 (blue). 
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Nanopore Dynamic 
Range (run) 
NP100 70-200 
NP200 100-400 
NP400 200-800 
NP800 400-1,600 
NP1000 500-2,000 
Table 2.1 Dynamic range of various qNano nanopores. 
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Figure 2.10 Histogram showing time course of eNP swelling over 5 d measured by 
qNano. Particles maintained at pH 5.0 for 0 d (blue), 3 d (red), and 5 d (green) are sized 
on small (white fill) and large (colored fill) nanopores. Both particle size and distribution 
increase with prolonged exposure to pH 5.0. Particles maintained at pH 7.4 showed no 
change in diameter or distribution over 5 d (data not shown). Average eNP diameter 
increases with swelling time at pH 5.0 (Fig. 2.18) 
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Figure 2.11 Histograms showing the concentration of eNPs maintained at pH 5.0 
measured by qNano. Particle concentration measured on the small nanopore (solid bars) 
decreases with time while eNP concentration measured on the large nanopore (hatched 
bars) increases with time (left). Overall particle concentration decreases with increased 
swelling time (right). (n = 3, mean± SD). 
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Figure 2.12 (Top, blue box) Schematic representation for the proposed mechanism of 
increased eNP translocation duration. Unswollen eNPs at pH 7.4 (top, blue box) do not 
translocate through a pore smaller than their diameter (left) but will readily pass through 
a large pore (right) resulting in a momentary sharp spike in the current signal (green 
trace). (Bottom, red box) As with unswollen particles, swollen eNPs at pH 5.0 do not 
translocate through a pore smaller than their diameter (left) but will readily pass through 
a large pore (right) resulting in a momentary sharp spike in the current signal (green 
trace, right). However, swollen eNPs also exhibit unique translocation behavior and can 
be "squeezed" through a pore close to the diameter of the particle (middle, purple), 
which results in a longer translocation through the pore and a broadened spike in the 
current (green trace, middle). 
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Figure 2.13 (Top, red box) Representative signal traces from swollen eNPs that pass 
cleanly and "un-squeezed" through the pore-sharp peaks ( ~0.1 ms FWHM) denote 
translocation of a nanoparticles. (Bottom, purple box) Signal traces from swollen eNPs 
being "squeezed" through the pore-broad peaks (~50 ms FWHM) are indicative of soft 
swollen particles translocating the pore at reduced speed. 
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Figure 2.14 Resistive pulse sensing quantification of eNP size and translocation duration 
for ~150 run eNPs maintained for 3d at pH 7.4 (blue) and pH 5.0 (red, purple) using a 
qNano. Particles pass cleanly through a pore much larger than the diameter of the particle 
for both unswollen (blue) and swollen (red) eNPs. The nanopore is dynamically 
decreased in size until swollen eNPs (purple) are squeezed through the nanopore 
exhibiting increased translocation durations. Unswollen particles do not exhibit this 
"squeezing" behavior. 
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Figure 2.15 Ratio of peak I area to peak III area for covalently encapsulated pyrene-eNPs 
maintained at pH 7.4 (blue) and pH 5.0 (red) for 3 d. Larger values for the ratio of peak I 
area to peak III area are indicative of more hydrophilic environments. The ratio of peak I 
area to peak III area increases with time as particles swell at pH 5.0 reflecting the 
significant (P < 0.001) increase in the hydrophilicity of swollen vs. unswollen eNPs. (n = 
3, mean± SD). 
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Figure 2.16 Synthesis schematic of the eNP monomer, (5-methyl-2-(2,4,6-
trimethoxyphenyl)-1 ,3-dioxan-5-yl)methyl methacrylate, and crosslinker, 1,4-phenylene 
bis(2-methy lacry late), as well as iodinated monomer 2-(3-acetamido-2 4 6-
, ' 
triiodo benzamido )ethy 1 methacrylate. 
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Figure 2.17 Nanoparticle size, as measured by DLS, is controlled by: the relative ratio of 
surfactant to monomer used in the mini-emulsion polymerization-in each case the mass 
of monomer used is 50 mg (left); and, the sonication energy used to create the mini-
emulsion (right). 
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Figure 2.18 Average eNP diameter increases with swelling time at pH 5.0. 
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Small Pore, NP400 Large Pore, NP800 
Day macroscopic applied applied macroscopic applied applied 
stretch voltage pressure stretch voltage pressure 
(mm) (V) (cmH,O) (mm) (V) {em H,O) 
0 44.29 0.90 3, 6, 9 48.14 0.48 3, 6, 9 
3 45.44 0.90 3, 6, 9 48.14 0.48 3, 6, 9 
5 45.44 0.90 3, 6, 9 48.14 0.48 3, 6, 9 
Table 2.2 qNano parameters used to measure the time course size and concentration 
distribution of eNPs maintained at pH 5.0 and pH 7.4 for 0, 3, and 5 d. 
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Figure 2.19 a) Normalized pyrene-methacrylate emission spectrum for pyrene in: pH 5.0 
10 rnM buffer (orange diamonds), acetone (blue circles), n-hexane (green dashes), and 
covalently encapsulated in unswollen (yellow triangles) and swollen (red squares) 
eNPs. b) Standard curve for (peak I area)/(peak III area) for pyrene-methacrylate v. 
polarity index of various solvents. (n = 3, mean± SD) 
67 
CHAPTER 3: In Vitro Activity ofPaclitaxel-Loaded Polymeric Expansile 
Nanoparticles in Breast Cancer Cells 
3.1 Chapter Forward 
This chapter is comprised of several studies looking at the in vitro efficacy of 
paclitaxel-loaded expansile nanoparticles (Pax-eNPs) as well as the internalization of 
eNPs in tumor cells grown in vitro. To investigate the mechanism of eNP uptake, we 
used pharmacologic inhibitors to shut down individual uptake pathways and thereby 
reveal the cellular routes primarily responsible for eNP internalization. In addition to 
investigating the mechanism of uptake, several insightful pieces of data were collected 
demonstrating eNP localization to lysosomes (an important fact due to the design of the 
eNP, which depends upon lysosomal/pH-triggered drug-release) and efficacy of Pax-
eNPs against actual patient samples obtained thru Dr. Colson. Concurrently with this 
work, Rong performed several animal studies showing the superiority of Pax-eNPs 
compared to the clinical formulation of paclitaxel in Cremophor/ethanol (Pax-C/E) in 
treating microscopic and established disease and reducing lymphatic metastases. 147 
Despite the use of breast cancer in both sets of work (in vitro and in vivo), the data were 
too many and the "stories" too disparate to combine into a single paper. Consideration 
was given to submitting concurrent papers as an in vitro/in vivo pair, but we eventually 
settled upon separate submissions. The in vivo work was published in Biomaterials in 
2013, and the in vitro work was published in Biomacromolecules in 2013 and appears 
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below, as printed, with sections numbered and abbreviations and formatting made 
consistent with the current document. Special recognition is given to Kimberly Ann V. 
Zubris, Ph.D., for her efforts in collecting much of this data. 
3.2 Introduction 
Nanoparticle (NP) drug delivery systems are a promising technology platform to 
overcome potential drug inadequacies and provide improved specificity, solubility, 
0 0 0 0 0 114 116 118 125 127 130 166-168 
stabthty, and appropnate pharmacokmettcs. ' ' ' ' ' ' One field of 
medicine where drug delivery systems can have a significant influence is cancer therapy. 
Breast cancer is the most common malignancy in women and ranks second in cancer-
related deaths, impacting the lives and families of nearly 200,000 U.S. women and 1.2 
million women worldwide. 169 Most patients undergo surgery (i.e., lumpectomy, 
mastectomy, radical mastectomy), as well as treatment with adjuvant therapies such as 
local radiation or systemic therapy, including biologic therapy, chemotherapy, and 
hormone therapy in order to prevent recurrence or for treatment of advanced tumors not 
amenable to resection. Several factors influence the effectiveness of chemotherapy in 
breast cancer, specifically tumor size, extent of lymph node involvement, the presence or 
absence of different cell receptors, and the method of delivery. 
Due to their potential ability to improve the delivery of chemotherapeutic agents 
(e.g., methotrexate, doxorubicin, paclitaxel; Pax) to cancer cells while maintaining 
antitumor efficacy and minimizing toxicity to healthy tissues, researchers are 
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. . . NP c 1 . f 1 . d 115 166 170-171 Th f NP mvestlgatmg 10rmu atwns o severa anticancer rugs. ' ' e use o s 
in breast cancer therapy has the potential to allow simultaneous tumor targeting and drug 
delivery. 172 NP formulations of several common breast cancer chemotherapeutic agents, 
including nanoparticle-albumin-bound (nab )-paclitaxel, (Abraxane) 173-174 poly(L-
glutamylglutamate)-conjugated paclitaxel, 175 liposomal doxorubicin, and PEG-ylated 
liposomal doxorubicin, 176-177 and doxorubicin-loaded, folate-conjugated polymeric 
micelles 178 have demonstrated improved efficacy and fewer toxic side effects compared 
with their conventional formulations. 
A particular clinical problem with the use of Pax delivered in its clinical 
formulation of Cremophor/ethanol (C/E) is the minimal amount of Pax that reaches the 
tumor. In order to maximize intratumoral drug delivery, paclitaxel-loaded expansile 
nanoparticles (Pax-eNPs) were designed to release Pax locally in the presence of a 
mildly acidic pH, as occurs within the tumor cell endosome. 108 We have recently 
reported the in vivo efficacy and superiority of Pax-eNPs compared to Pax-C/E against 
human triple negative breast cancer in both microscopic and established murine breast 
cancer models. 147 Specifically, in vivo growth rates of the primary tumor following Pax-
eNP treatment in the microscopic prevention model were significantly slower than the 
equivalent dose of Pax-C/E administered locally or the 3-fold higher Pax-C/E dose given 
systemically. Moreover, only 25% of Pax-eNP treated mice had clinical evidence of 
tumor compared to 67 and 92% of the mice following treatment with local or systemic 
Pax-C/E, respectively. In the established model, the Pax-eNP treated mice exhibited 
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smaller tumors and significantly slower tumor growth than all other treatment groups. 
The average tumor doubling time in Pax-eNP treated mice was about 18 days compared 
to 7 days with locally or systemically administered Pax-C/E. In addition, migration of 
Pax-eNP to axillary lymph nodes resulted in higher intranodal Pax concentrations (9.2-
fold greater) and a significantly lower incidence of lymph node metastases (2.5-fold less) 
compared to the Pax-C/E treatment group. These results provide motivation to further 
study this NP drug delivery system by ascertaining the mechanism of cellular uptake of 
eNPs, and evaluating efficacy against other breast cancer cell lines. Therefore, in this 
study we have investigated the cellular uptake, Pax delivery, and in vitro cytotoxic 
activity of Pax-eNPs against three different established human breast adenocarcinoma 
cell lines (MDA-MB-231, MCF-7, and SK-BR-3) as well as non-immortalized cancer 
cells isolated from the pleural effusions of two breast cancer patients. 
3.3 Materials and Methods 
3. 3.1 General Procedures and Materials. 
All chemicals were purchased from Sigma-Aldrich or Lancaster Synthesis and 
used without further purification. MDA-MB-231 breast adenocarcinoma cells (ATCC) 
were cultured in Leibovitz's L-15 media supplemented with 10% fetal bovine serum 
(FBS), 3.5 g of glucose/L, and 2.5 rnL of penicillin-streptomycin/L (complete growth 
media) at 37 oc and atmospheric air. Cell viability studies were performed using a 
CellTiter 96 AQueous One Solution tetrazolium-based assay (Promega) where the 
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absorbance was measured at 492 run via a Beckman Coulter AD 340 96-well plate 
reader. In this MTS assay, the measured absorbance is proportional to the total metabolic 
activity of the cells in the well, giving a relative measure of the viable cell population in 
each well. 
3. 3. 2 Synthesis of Paclitaxel-Loaded Nanoparticles. 
Nanoparticles were prepared using a miniemulsion polymerization method. 108 
First, 50 mg of monomer (5-methyl-2-(2,4,6-trimethoxyphenyl)-[1 ,3]-5- dioxanylmethyl 
methacrylate) and 0.5 mg of cross-linker (1,4-0- methacryloylhydroquinone) were 
dissolved in 0.5 mL of CH2Cb. For the encapsulation of Pax as 5% Pax-eNPs, 2.5 mg of 
the drug was dissolved in the CH2Cb along with the monomer and cross-linker. This 
organic solution was added to 2 mL of a 10 mM aqueous buffer solution containing 
sodium dodecyl sulfate (SDS). By changing the amount of SDS, the size of eNPs can be 
varied, and for these experiments we selected eNPs in the 50 run range by using 5-10 mg 
ofSDS. This mixture was sonicated for 10 min (1 s pulses with a 2 s delay) with 20 W of 
power under an argon blanket to create the mini emulsion. Using a base-catalyzed 
reaction following sonication, 20 J.!L of a 200 mM aqueous ammonium peroxodisulfate 
(APS) solution and 2 J.!L of N,N,N',N'- tetramethylethylenediamine (TEMED) were 
added to the emulsion and stirred under an argon blanket for 2 hr. Following 
polymerization, the suspension was stirred overnight while open to the atmosphere to 
allow for evaporation of the remaining solvent. The resulting polymeric NPs were 
dialyzed against 5 mM pH 8.0 phosphate buffer over two days to remove excess 
surfactant, salts, and non-encapsulated drug. When synthesizing rhodamine-labeled 
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nanoparticles (Rho-eNPs), 0.05 mg of PolyFluor 570 (methacryloxyethyl tricarbonyl 
rhodamine B; Polysciences, Inc.) was dissolved in the CH2Ch along with the monomer 
and cross-linker before addition of this organic phase to the aqueous phase. The size of 
the NPs was determined by dynamic light scattering (DLS) and scanning electron 
microscopy (SEM). By DLS the eNPs were on average ;::;I 00 nm in diameter. SEM 
analysis revealed 1 00 nm as well as many smaller eNPs, and the average diameter and 
standard deviation was determined to be 32 ± 23 nm via sizing 200+ particles in a 
viewing field (Fig. 3.1 ). 
3. 3. 3 Measurement of Paclitaxel Encapsulation Efficiency. 
A 300 )..tL sample of eNPs was lyophilized and 1 mg of the dried NPs was 
weighed on a microbalance. The sample of NPs was dissolved in 200 )..tL of CH2Ch and 
mixed with 0.5 mL of 1:1 acetonitrile/water. The dichloromethane was evaporated while 
stirring under a stream of nitrogen, and the precipitated polymer was removed by 
centrifuging the samples at 5000 x g for 10 min. The concentration of Pax in the 
remaining acetonitrile/water phase was determined by high performance liquid 
chromatography (HPLC). HPLC detection of Pax was performed using a 20 min linear 
gradient from 60:40 to 35:65 water/acetonitrile at a flow rate of 1.0 mL/min on a 
MetaChem 5 Taxsil 250 x 4.6 mm column and Varian ProStar HPLC with detection at 
210-218 nm. This process also confirmed the ability to synthesize Pax -eNPs without 
degradation of the drug as evidenced by the observation of a single Pax peak on all HPLC 
traces. 
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3. 3. 4 Confocal Laser Microscopy. 
MDA-MB-231 cancer cells were cultured in 6-well plates containing 2 mL of 
complete growth medium. Before seeding the cells onto the 6-well plates, a sterile 22 x 
22 mm glass coverslip was placed on the bottom of each well. After 2 days of incubation, 
cells were treated for 8 hr with eNPs loaded with Oregon Green 488 conjugated-
paclitaxel (PaxOG-eNPs) versus media only as a control. At the end of the treatment 
period, the media was aspirated from the wells and the coverslips were moved to new 
wells in a 6-well plate. The coverslips were rinsed with phosphate buffered saline (PBS; 
2 mL x 1) and incubated for 20 min with 2 mL of 3. 7% neutral buffered formalin to fix 
the cells. The coverslips were washed with PBS (2 mL x 1) and PBS containing calcium 
and magnesium (complete PBS; 2 mL x 1) and then incubated with 50 flg/mL 
concanavalin A-Alexa Fluor 647 conjugate (Invitrogen) in PBS (1 mL) for 5 min in order 
to identifY the cell membrane. Lastly, the coverslips were washed with PBS (2 mL x 1) 
and complete PBS (2 mL x 1) before being mounted on glass microscope slides for 
imaging. The fixed and stained cells were imaged on an Olympus FluoView FV1000 
scanning confocal laser microscope using 488 and 633 nm lasers to detect PaxOG and 
Concanavalin A-Alexa Fluor 647 independently. 
3.3.5 Quantitative Measurement ofNanoparticle Uptake by Flow Cytometry. 
Flow cytometry was used to quantifY the cellular uptake of rhodamine-labeled 
eNPs in MDA-MB-231 human breast adenocarcinoma cells. Cells at 80000 cells/mL 
were cultured in 6-well plates containing 2 mL of complete growth media per well. After 
allowing the cells to adhere and grow for 24 hr, the media was removed from the wells 
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and replaced with 2 mL of media containing 50 J..tg/mL rhodamine-eNPs (polymer 
concentration). The cells were incubated with the NPs for 2, 4, 8, 12, or 24 hr at either 37 
or 4 °C. Control experiments not containing NPs were also performed. At the end of the 
incubation time, the media was removed and the cells were washed 3X with 2 mL PBS 
before harvesting by trypsin treatment. The cell suspensions were centrifuged at 250g for 
5 min before being re-suspended in 1 mL PBS and fixed in 3.7% paraformaldehyde for 
15 min. After fixation, all samples were washed twice with cold F ACS buffer (PBS with 
1% BSA) by centrifugation at 250g for 5 min and re-suspended in F ACS buffer at 1 x 
1 o6 cells/mL. Cell-associated nanoparticle content was immediately assayed by flow 
cytometry using a Beckman-Coulter (Dako) MoFlo high-speed cell analyzer/sorter. 
3. 3. 6 Confirmation of Late-Endosome Localization of Rho-eNP. 
To determine if the rhodamine-labeled-eNPs (Rho-eNPs) were observed in the 
late endosome, a second imaging experiment was performed. The cells were seeded at 
20000 cells in glass bottom dishes (35 mm diameter with coverslip No. 1.5, MatTek 
Corporation, Ashland, MA) with complete L-15 media for 24 hr at 37 °C in 5% C02. 
Cells were incubated with Rho-eNP for another 24 hr. The dishes were washed twice 
with phenol-red-free culture media, and twice with HBSS. Cells were stained with 
Hoechst 33342 (Life Technologies, Carlsbad, CA) and Alexa Fluor 633 conjugated wheat 
germ agglutinin (WGA 633, Life Technologies, Carlsbad, CA) for identification of the 
nucleus and cell membranes, respectively. LysoTracker Green DND-26 (Life 
Technologies, Carlsbad, CA), a green dye that stains acidic compartments, was added to 
achieve a fmal concentration of 50 nmol/mL in the culture media at 15 min prior confocal 
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Imagmg. Confocal microscope Images were obtained with Zeiss LSM 510 inverted 
confocal laser scanning microscope with Plan-Apochromat lOx/0.45 or C-Apochromat 
40 x 1.2 W corr lens (Carl Zeiss Microscopy, Thornwood, NY). Z-stack images were 
obtained for the analysis of co-localization. Velocity 6.0.1 software (PerkinElmer Inc., 
Waltham, MA) was utilized to quantify co-localization with calculation of the coefficient 
parameter "MX", which indicates percentage of Rho-eNPs in late endosome. A total of 
2-3 representative fields were selected in each culture dishes for the co-localization 
analysis. 
3. 3. 7 In Vitro Cell Viability. 
Nanoparticle cytotoxicity was evaluated using MDA-MB-231, MCF-7, and SK-
BR-3 human breast adenocarcinoma cell lines in culture. Cells were plated at 30000 
cells/mL in 96-well plates containing 100 J..LL of complete growth media at 37 °C. The 
culture media and gas exchange conditions used for the cell lines were Leibovitz' s L-15 
medium in atmospheric air (MDA-MB-231), EMEM in 5% C02 (MCF-7), and McCoy's 
5A medium in 5% C02 (SK-BR- 3). After culture for 24 hr, the media was removed from 
the wells and replaced with complete growth media containing a known concentration of 
(1) drug-free eNPs, (2) Pax-eNPs, or (3) free Pax (diluted from a stock solution of 1 
mg/mL paclitaxel in DMSO) without nanoparticles. Media alone controls were also 
included. After 7 d of exposure, the media was removed from the wells and replaced with 
100 J..LL of fresh media, followed by the addition of 20 J..LL of Cell Titer 96 AQueous One 
Solution (Promega) in order to assess viability using a standard MTS assay. 
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3.3.8 Pleural Effusion In Vitro Cell Viability. 
Pleural fluid was collected from "de-identified" breast cancer patients, under an 
approved discarded specimen IRB protocol through Dana Farber Cancer Institute at the 
time of therapeutic thoracentesis performed in two patients with known malignant 
effusion due to breast cancer as determined on previous cytopathologic characterization. 
Tumor cells were isolated with centrifugation and Ficoll gradient separation, washed and 
seeded in culture flasks in serum-free culture media overnight. A 1 min selective 
trypsinization was performed to remove remaining stromal cells, and serum-positive 
culture media was added. Cells were grown to near-confluence, trypsinized, and used for 
in vitro viability assays. Cells were plated at 30,000 cells/mL in 96-well plates containing 
100 ).!L of complete growth media at 37 oc and 5% C02. After culture for 24 hr, the 
media was removed from the wells and replaced with media alone or media containing a 
known concentration of drug-free eNPs or Pax-eNPs, or free Pax. After 7 d of exposure, 
the media was removed and an MTS in vitro cell viability assay as described above was 
performed. 
3. 3. 9 Determination of Endocytosis Inhibitor Concentration. 
To determine nontoxic doses of the pharmacological endocytosis inhibitors, 
viability assays were performed. MDA-MB-23 1 breast cancer cells were initially plated 
in 96 wells at a concentration of 30000 cells/mL in complete L-15 media. After allowing 
the cells to adhere and grow for 24 hr, the media was removed from the wells and 
replaced with 2 mL media containing a range of inhibitor concentrations. Cells were 
incubated with the inhibitors for 4 hr at 3 7 °C. Controls not containing inhibitors were 
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also performed. At the end of the incubation time, the media was removed from the wells 
and the cells were washed 3 x with 2 mL PBS before fresh culture media was added. 
After 48 hr, the media was removed from the wells and replaced with 100 f.lL of fresh 
media, followed by the addition of 20 f.lL of CellTiter 96 AQueous One Solution 
(Promega) in order to assess viability using a standard MTS assay. The highest inhibitor 
concentration, which was not itself cytotoxic, was chosen for all subsequent inhibitor 
assays. 
3. 3.10 Determination of Uptake Pathway via Endocytotic Inhibition. 
For cellular uptake experiments, MDA-MB-231 breast cancer cells were plated in 
6-well plates at 30000 cells/mL in complete L-15 media (2 mL) and allowed to adhere for 
24 hr. Cells were preincubated in the presence of the inhibitors for 1 hr before exposure 
to a 50 f.lg/mL (polymer concentration) suspension of rhodamine-labeled eNPs in full 
growth media for an additional 4 hr, during which time an inhibitor was also present. The 
pharmacological inhibitors were used at the following concentrations: sodium azide 
0.01 %, 2-deoxyglucose 20 mM, chlorpromazine 10 f.!M, hexamethylene amiloride 20 
f.!M, wortmannin 10 f.!M, genistein 50 f.!M, and methyl-~-cyclodextrin 5 mM. Following 
nanoparticle exposure, the media was removed and all wells were washed 3X with 2 mL 
PBS before harvesting by trypsin treatment. Cell suspensions were centrifuged at 250g 
for 5 min before being re-suspended in 1 mL of PBS and fixed in 10% paraformaldehyde 
for 15 min. After fixation, all samples were washed with cold F ACS buffer (PBS with 
1% BSA) by centrifugation at 250g for 5 min and re-suspended in F ACS buffer (1 x 106 
cells/mL). Cell-associated nanoparticle content was immediately assayed by flow 
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cytometry using a Beckman-Coulter (Dako) MoFlo high-speed cell analyzer. 
3. 3.11 Confirmation of Uptake Pathway via Endocytosis Marker Colocalization. 
Laser scanning confocal microscopy was used to directly visualize the co-
localization of the expansile nanoparticles with an endocytotic fluid phase marker. MDA-
MB-231 cells were plated in complete L-15 media at 25000 cells/mL in collagen-coated, 
glass-bottom, 35 mm dishes (MatTek, Ashland MA) and allowed to adhere for 24 hr at 
37 °C. Cells were treated with Rho-eNPs (50 11g/mL polymer concentration) in the 
presence of the endocytosis marker Cascade Blue hydrazide (5 11M). Following 
nanoparticle/ Cascade Blue exposure for 4 hr, the media was removed and all wells were 
washed 2X with 2 mL of PBS before fixation in 3.7% formalin for 15 min. Cells were 
imaged using an Olympus FluoView FVIOOO laser scanning confocal microscope m 
sequential mode to eliminate emission cross-talk between the various dyes. 
3.4 Results and Discussion 
Pax is used clinically in the treatment of breast cancer but suffers from poor 
aqueous solubility. We therefore selected Pax for use in our eNP delivery system for this 
study. A mild mini emulsion polymerization process allowed us to successfully 
encapsulate Pax without degradation, as determined by HPLC, following our published 
procedure. 108 Specifically, a base-catalyzed free-radical polymerization method was 
employed. Pax was encapsulated at a loading level of 5% (wt/wt monomer) by dissolving 
the drug in the organic phase along with the monomer and cross-linker prior to 
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emulsification. The encapsulation efficiency was found to be 98.3 ± 3.4% (mean± SD). 
These nanoparticles of 20-100 nm were designed to undergo expansion in a pH-
dependent fashion with release of the encapsulated drug at pH 5, as found within the 
cellular endosome, thereby achieving intracellular drug release (Fig. 3.1). 108, 110, 179 
We first investigated the ability of Pax-eNPs to enter tumor cells and reach the 
late endosomal compartments where their pH-triggered release of Pax would be 
activated. In this confocal microscopy experiment, the triple negative human breast 
cancer cells, MDA-MB-231, were treated with Rho-eNPs and then stained with Hoechst 
33342, Alexa Fluor 633 conjugated wheat germ agglutinin, and LysoTracker Green 
DND-26 for identification of the nucleus, cell membrane, and late endosome, 
respectively (Fig. 3.2). The red fluorescent signal from the eNPs is clearly observed 
within the cells confirming uptake. Furthermore, the green fluorescent signal from the 
LysoTracker and the red fluorescent signal from the eNPs were observed from the same 
position for a number of cytosol locations. The average co-localization efficiency was 
determined to be 52 ± 5% (mean ± SEM), indicating that 52% of the Rho-eNPs were 
located in the late endosome. In a second confocal microscopy study, eNPs were loaded 
with PaxOG and exposed to the MDA-MB-231 cells. Following incubation for 8 hr with 
the nanoparticles, the MDA-MB-231 cells were washed, fixed, and stained with 
Concanavalin A-Alexa Fluor 647 to highlight the cell membrane (Fig. 3.3). As can be 
seen in the composite confocal laser microscopy image on the bottom right of Figure 3.3, 
the extracellular membrane is distinctly seen in red, while the fluorescent drug (which 
appears green) is distributed evenly throughout the cytoplasm, indicating successful 
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delivery of Pax to the cytoplasm. 
Flow cytometry was subsequently employed to quantify eNP cellular uptake. 
After exposing MDA-MB-231 human breast cancer cells to NPs covalently labeled with 
rhodamine for 2, 4, 8, 12, or 24 hr, the cells were analyzed. As shown in Figure 3.4, the 
number of cells demonstrating eNP uptake progressively increased as a function of 
incubation time with 36.20 ± 0.9% of cells experiencing particle uptake within 24 hr at 
3 7 °C. In contrast, when cells were incubated with eNP at 4 °C to decrease metabolic 
activity, cellular uptake was significantly reduced to <1% at all time points (P < 0.001). 
The decrease in intracellular eNP detected at low temperature indicates that the cellular 
uptake of the eNPs is an energy-dependent process. We also evaluated the uptake of 
eNPs in human mammary epithelial cells, MCF-10A, as a control cell line. Similar 
uptake was observed under these in vitro conditions between the MCF-10A and MDA-
MB-231 lines. Given that the eNPs are taken up by breast cancer cells and that Pax can 
be delivered intracellularly using the eNPs, we evaluated the dose-dependent antitumor 
activity of Pax-eNPs in vitro using three human breast cancer cell lines that differ in 
terms of the key clinical determinants of estrogen receptor and Her-2/neu expression: 
MDA-MB-231, MCF-7, and SK-BR-3. After 7 d of exposure to Pax-eNPs, unloaded-
eNPs, or Pax alone, the cell viability was determined using a colorimetric MTS assay. 
Unloaded (drug-free) eNPs failed to exhibit cytotoxicity against any of the cell lines at 
the concentrations tested (0.01 to 100 f.lg/mL polymer concentration), indicating that the 
NPs themselves were not toxic to the cells. Furthermore, as shown in Figure 3.5, Pax-
eNPs (5 wt% Pax/wt polymer) resulted in significant cytotoxicity against each of the cell 
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lines tested. The cytotoxicity profiles resembled that of free Pax with the calculated IC50 
ofPax-eNPs being -10, 7.5, and 5 ng/mL of Pax for the MDA- MB-231, MCF-7, and 
SK-BR-3 cell lines, respectively, compared to 2.5-5 ng/mL for free Pax, demonstrating 
that Pax is released from the eNP and is effective. The IC50 obtained with the MDA-MB-
231 cells agreed with our previous result obtained with a MDA-MB-231-Luc cellline. 147 
A similar increase in the IC5o compared to Pax has been observed with other cell lines 
(A549) and attributed to the expanded eNP acting as reservoir for the drug, thereby, in 
fact, limiting the immediate bioavailability of the drug. 110 Thus, the performance of Pax-
eNPs was not significantly better than Pax alone in this in vitro model, and, furthermore, 
Pax-eNPs and Pax were both cytotoxic to MCF-lOA cells, as this cell line is sensitive to 
Pax. 180 Despite this lack of eNP delivery system, we observed a significant improvement 
in Pax performance when delivered using eNPs in three separate in vivo MDA-MB-231-
Luc tumor models (i.e., microscopic disease, established disease, and lymph node 
metastases). 147 The superior performance in vivo may stem from the ability of eNPs to 
maintain high concentrations of the drug within tumor tissue for prolonged periods of 
time. This slow release of drug over time may also be the reason eNPs perform poorly 
compared to free drug in long-term in vitro assays. These results speak to some of the 
limitations in performing only in vitro assessments to characterize a NP drug delivery 
system, where drug and NP are not subjected to biodistribution in vivo, clearance, or 
degradation and are confined to the culture well with the tumor cells for as long as the 
assay is performed. 
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We next evaluated the cytotoxicity of Pax-eNPs against cultured cells obtained 
from the pleural effusions of two different breast cancer patients. Tumor cell samples 
were collected at the time of a therapeutic thoracentesis performed in patients with 
known malignant effusions due to breast cancer as determined on previous 
cytopathologic characterization. Patient 1 had a poorly differentiated invasive ductal 
carcinoma that was estrogen receptor, progesterone receptor, and HER2 negative and had 
failed prior treatment that included Adriamycin, cytoxan, Pax, gemcitabine, and cisplatin. 
Patient 2 had a moderately differentiated invasive ductal carcinoma that was estrogen 
receptor and progesterone receptor positive and had previously failed treatment regimens 
that included letrozole, zoledronic acid, capecitabine, tamoxifen, protein-bound Pax, 
doxorubicin, and fulvestrant. 
Similar to the in vitro viability assays with the established cell culture lines, fresh 
tumor cells from malignant pleural effusion were exposed to unloaded-eNPs, 5% Pax-
eNPs, Pax alone, or were left untreated for direct viability comparison. After 7 d of 
exposure, cell viability was determined using the MTS assay; the results of exposure of 
cells from Patients 1 and 2 to the various treatment groups are displayed in Figure 3.6. 
For both patient samples, the Pax-eNPs had a cytotoxicity profile similar to the profile of 
free Pax but with a slight rightward shift. The calculated Pax-eNP ICso value was -9 
ng/mL. This demonstrates that the Pax-eNPs are able to deliver encapsulated drug and 
effectively inhibit in vitro proliferation of breast cancer cells directly harvested from 
patients even though their tumor had failed systemic Pax regimens. 
Having established the in vitro efficacy of Pax-eNPs, we next investigated the 
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mechanism of eNP cellular uptake. Based on prevwus reports, size, charge, shape, 
material composition, and surface chemistry are key parameters that determine the 
mechanism and rate of cellular uptake of nanomaterials. 181 -183 We determined the 
mechanism of eNP uptake by using several different types of endocytotic inhibitors to 
block various cellular uptake pathways followed by flow cytometry quantification. 
Generally, endocytosis can be divided into two broad categories: phagocytosis (the 
uptake of large particles) and pinocytosis (the uptake of fluids and solutes). Given the 
small size of eNPs, pinocytosis is most relevant to these cells, having multiple forms 
depending on the cell origin and function. The most current classification system for 
pinocytosis is based on the proteins involved in the different endocytotic pathways and is 
divided into clathrin-dependent or clathrin-mediated endocytosis and clathrin-
independent endocytosis. 183-185 Clathrin-mediated endocytosis is the "classical route" of 
cellular entry, which is present and inherently active in all mammalian cells. 184-185 
Mechanistically, it involves the engulfment of receptors associated with their ligands in a 
d 0 186 coate pit. 
The clathrin-independent pathways are further classified as (1) caveolae-mediated 
endocytosis, (2) macropinocytosis, and (3) clathrin- and caveolae-independent 
endocytosis. 184 Caveolae-mediated endocytosis relies on the presence of the hairpin-like 
membrane protein, caveolin-1, which is necessary for the biogenesis of the caveolae. 185' 
187 Macropinocytosis is a special case of clathrin- and caveolae-independent endocytosis, 
hi h . . . . d b th . . . f . ki 188-189 Th w c IS lllltlate y e transient activatiOn o receptor tyrosme nases. e 
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receptor activation triggers formation of membrane ruffles that protrude to engulf the 
surrounding fluid in the extracellular milieu, forming large (0.5-1 0 ).!m) intracellular 
1 d . 188 190 Th fi 1 . . 1 .fi . 1 hri vacuo es terme macropmosomes. ' e rna pmocytos1s c ass1 1catwn, c at n-
and caveolae-independent endocytosis, includes those pathways not usually classified by 
the above criteria. 
Exclusion of specific endocytotic mechanisms is a distinct and powerful 
technique to elucidate endocytosis. This can be achieved by using various pharmacologic 
inhib. f d . h . 1 d h . 1 b. 1 . 1 182 191-194 Thi 1tors o en ocytos1s t at me u e c emtca or 10 ogtca agents. ' s 
method offers several advantages over other techniques, such as genetic manipulation, 
because exposure to pharmacologic inhibitors affects all cells during exposure. This 
results in homogeneous cell responses and less need for compensatory mechanisms, 
because the cells are usually exposed to inhibitors for only a short time period. 191 One 
limitation with the use of chemical inhibitors is that they are rarely selective and often 
disturb multiple endocytosis pathways. 191 Therefore, it is essential to utilize a 
combination of such inhibitors to validate the inhibitory mechanism and to establish 
effective inhibitor concentrations in particular cell types. 
The optimal inhibitor concentrations (as defmed by a maximum dose while 
maintaining at least 75% cell viability compared to non-treated cells) were identified via 
cell proliferation assays. Based on this criterion, the pharmacological inhibitors were 
used at the following concentrations: sodium azide 0.01 %, 2-deoxyglucose 20 mM, 
chlorpromazine 10 ).!M, hexamethylene amiloride 20 ).!M, wortmannin 10 ).!M, genistein 
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50 J.!M, and methyl-~-cyclodextrin 5 mM. For the cellular uptake experiments, cells were 
pre-incubated in the presence ofthe inhibitors for 1 hr before exposure to a suspension of 
Rho-eNPs in media for 4 hr, during which time, the inhibitors were also present. 
Following nanoparticle exposure, the media was removed and the cells were washed, 
fixed, and analyzed by flow cytometry. The cellular uptake data were expressed as the 
percentage of uptake relative to cells that had not been inhibited (positive uptake control). 
Consistent with the eNP uptake studies performed at 4 °C, the results in Figure 
3. 7 suggest that endocytosis is the dominant pathway of cellular uptake, because 
treatment with NaN3/2-deoxyglucose almost completely diminished eNP uptake (>95% 
decrease in uptake). Significant inhibition of eNP uptake ( -80% inhibition) was also 
observed in the presence of wortmannin, which blocks the action of phosphoinositide 3-
kinases (PI3Ks). PBK is required for spontaneous surface ruffling, an integral part of 
macropinocytosis, suggesting that eNPs enter the cell through macropinocytosis. Because 
loss of PBK function is known to block internalization of ligands needed for the clathrin-
and caveolae-mediated pathways, 195 confirmation of macropinocytosis involvement was 
obtained by the use of a more selective ion channel inhibitor, hexamethylene 
amiloride. 191 Similar to wortmannin, treatment with this compound afforded an -60% 
inhibition of particle uptake, thus confirming a role for macropinocytosis in eNP uptake. 
Similarly, uptake was reduced by -65% when cells were treated with methyl-~­
cyclodextrin, which inhibits cholesterol-dependent endocytosis by extracting cholesterol 
from the plasma membrane. Cholesterol is involved in membrane ruffling and actin 
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reorganization, among other endocytotic functions, 196 such that inhibition of eNP uptake 
b h 1 R 1 d · · 1 · d' · f · · 196-198 y met y -.... -eye o extnn IS a so m 1cat1ve o macropmocytos1s. In contrast, no 
reduction in nanoparticle uptake was observed when inhibiting specific caveolae-
mediated and clathrin-mediated pathways with either genistein or chlorpromazine, 
respectively, suggesting that these pathways do not play a significant role. Therefore, the 
pharmacological interference data presented above support macropinocytosis as a major 
pathway responsible for uptake of the eNPs. 
Finally, laser scanning confocal microscopy was used to directly visualize the 
intracellular trafficking of the eNPs based on the above results. The MDA-MB-231 cells 
were treated with Rho-eNPs in the presence of the endocytosis marker Cascade Blue 
hydrazide, a small-molecule fluid-phase uptake marker used for macropinocytosis 
visualization. When cells were co-incubated with nanoparticles and Cascade Blue, co-
localization of the Rho-eNPs and Cascade Blue was observed (Fig. 3.8). In addition, the 
co-localization results obtained with the LysoTracker Green DND-26 and Rho-eNPs 
discussed earlier (Fig. 3.3) showed that the eNPs localize to the late endosome. Both of 
these results support the conclusion that eNPs are actively brought into tumor cells via 
the macropinocytotic pathway. 
3.5 Conclusion 
The findings from theses studies provide important information on this delivery 
system while also highlighting some of the advantages and limitations of using in vitro 
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experiments to predict in vivo performance. First, eNPs are internalized in MDA-MB-231 
breast cancer cells primarily via the macro- pinocytosis pathway as confirmed by 
temperature-sensitive metabolic reduction, pharmacologic inhibitors, and fluid-phase and 
endosomal marker co-localization. Once internalized, eNPs enter the late endosome 
where the locally acidic environment results in particle expansion and liberation of their 
encapsulated Pax payload allowing it to reach the cytoplasm. This escape of Pax from the 
endosome to the cytoplasm is crucial to the successful performance of this delivery 
system because Pax acts by stabilizing microtubules in the cytoplasm and thereby 
preventing cell division and inducing apoptosis. Pax-eNPs release sufficient drug to 
induce cytotoxicity with an IC5o value of 10 ng/mL for MDA-MB-231 breast cancer 
cells. The Pax-eNP formulation was active against two other human breast cancer cell 
lines, which possess different estrogen receptor and Her-2/neu expression levels, as well 
as tumor samples harvested from two patients who had undergone prior treatment with 
Pax. It is important to note that, in all of these in vitro toxicity assays, the Pax-eNPs did 
not perform better than Pax alone. In these in vitro assays, the drug is unable to diffuse 
away from the local cellular environment, as happens rapidly in vivo, and therefore, 
sufficient time is provided for the Pax-eNPs or Pax to interact with the cell and lead to 
apoptosis. Nevertheless, in vitro experiments are generally easier and more rapidly 
accomplished than in vivo studies and allow greater knowledge of and control over 
experimental parameters, thereby affording a method to screen delivery system 
performance and pathways of uptake (rate, pathway, cellular localization). In vitro studies 
do not substitute for in vivo experiments and the results obtained in vitro may, or may 
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not, be good indicators of Pax alone in the in vivo studies but not the in vitro cytotoxicity 
experiments. 
These results, combined with our recently published in vivo studies, 147 provide a 
detailed account of the activity and performance of Pax-eNPs against human breast 
cancer. Additionally, Pax-eNPs have shown in vivo efficacy in several other murine 
. . 108 110 148 . 109 149 tumor models mcludmg non-small cell lung cancer, ' ' mesothelioma, ' and 
ovarian, 199 indicating broad anticancer applicability. Given these results, future 
experiments must focus on the development of scalable eNP synthesis, identification of 
suitable storage conditions, pharmacokinetic studies of encapsulated radiolabeled-Pax, 
and biodistribution studies of the eNP in a large animal model in order to move this 
technology closer to the clinic. 
89 
pH 5 
20 40 60 80 100 120 140 160 
eNP diameter (nm) 
Figure 3.1 (Top) Chemical structure of the polymeric expansile nanoparticles (eNPs) 
and the polymer cleavage reaction at pH 5 that leads to a swollen, expanded hydrogel 
state. The nanoparticles (light blue spheres; initially ~50 nm diameter) are taken up into 
cells where they undergo a hydrophobic to hydrophilic transition, swell several hundred-
fold in volume and release drug (yellow spheres). Not to scale. (Bottom) Scanning 
electron micrograph of the synthesized eNPs (scale bar = 200 nm) and histogram of 
particle size. 
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Figure 3.2 Localization study with Rho-eNPs after 24 hr incubation with cells using 
various fluorescent markers: (top, left) blue, Hoechst DNA stain; (top, right) green, 
LysoTracker stain; (bottom, left) red, Rho-eNPs; (bottom, right) white, WGA-633 cell 
membrane stain; (far, right) merged image displaying the fluorescence overlay of 
merged image from all four channels. 
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Figure 3.3 Confocal laser microscopy images of MDA-MB-231 breast cancer cells 
incubated for 8 hr with PaxOG-eNPs. (top, left) Intracellular PaxOG signal detected 
using 488 run laser. (top, right) Concanavalin A-Alexa Fluor 647 signal detected using 
633 run laser and marking the plasma membrane in red. (bottom, left) Differential 
interference contrast image. (bottom, right) Composite image showing intracellular 
delivery of the PaxOG to the cell cytoplasm. Scale bar = 10 ,...,m. 
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Figure 3.4 Uptake of Rho-eNPs in MDA-MB-231 breast adenocarcinoma cells 
determined via flow cytometry as a function of time and temperature. The% cells with 
eNP uptake at 4 °C is minimal(< 1 %) at all time points. Data displayed as mean± SD (n 
= 3). 
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Figure 3.5 Established breast cancer cell line viability relative to untreated controls 
following treatment for 7 d with varying concentrations of 5% Pax-eNPs. The same 
trends were observed when treating cells with free Pax. In contrast, unloaded-eNPs were 
not toxic (data shown is for MDA-MB-231 and was similar for the other two cell lines). 
Data are displayed as the mean± SD (n = 3). 
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Figure 3.6 Relative viability of tumor cells harvested from the malignant pleural effusion 
from breast cancer Patient 1 (left) and Patient 2 (right) treated with 5% Pax-eNP, 
unloaded-eNP, or Pax alone for 7 d. Data are displayed as the mean± SE (n = 3). 
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Figure 3. 7 Relative cell uptake of Rho-eNPs in the presence of inhibitors as determined 
by flow cytometry. Results are expressed as percentage of uptake compared to positive 
Rho-eNP control without inhibitors. Data displayed as mean± SD (n = 3). 
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Figure 3.8 Uptake of rhodamine-labeled eNPs after 4 hr of co-incubation in the presence 
of the fluid-phase marker Cascade Blue hydrazide: red, Rho-eNPs; blue, Cascade Blue 
hydrazide; white arrows indicate representative examples of co-localization (purple). 
Note: pseudo-color was used to enhance contrast and facilitate observation and the 
bottom image displays fluorescence overlay of the differential interference contrast 
Image. 
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CHAPTER 4. Paclitaxel-Loaded Expansile Nanoparticles Improve Survival in 
Peritoneal Mesothelioma via Localization to Tumors, Prolonged Residence Times, 
and Increased Intratumoral Drug Concentrations 
4.1 Chapter Forward 
This chapter focuses on the use ofpaclitaxel-loaded expansile nanoparticles (Pax-
eNPs) in mesothelioma and is the culmination of numerous animal studies that have been 
conducted over my five years in graduate school. One factor directing this study was the 
observation, described in the previous chapter, that Pax-eNPs are inferior to free Pax in 
vitro despite demonstrating significant superiority in vivo. The first section seeks to 
answer a frequently asked question: why does this occur? The simple answer is that in 
vitro systems are poor models for the complex physiology and pathophysiology existing 
in animals and humans. With ever more complex drug delivery systems comes a need for 
more complex models that are capable of elucidating and clarifying the advantages of 
these systems. Standard in vitro assays, as discussed in this chapter, are unable to do this 
in the case of eNP-mediated delivery of Pax. 
The second part of this chapter focuses on a second compelling question: why do 
eNPs localize to regions of intraperitoneal mesothelioma tumor? We show that the 
kinetics of this localization are characterized by rapid ( <4 hr) tumoral accumulation and 
prolonged (> 14 d) retention. The pathophysiology of tumor cells (e.g., rapid metabolism 
and division) is highlighted as one possible explanation for the fast accumulation. 
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Prolonged residence is hypothesized to result, in part, from eNP-induced alteration of the 
normallysosomal/autophagosomal pathways. 
The final section of this chapter investigates the efficacy of Pax-eNPs in a murine 
(i.e., mouse) model of established mesothelioma. This particular animal model is more 
rigorous and difficult to treat than previously used models. We examine the effects of: 1) 
titrating the overall drug dose as well as, 2) altering the treatment delivery schedule. The 
encouraging results from this work warrant further investigations that will be the subject 
of future academic or commercial studies. This work will be submitted for publication to 
Science Translational Medicine in the coming weeks. 
Lastly, Rong Liu is responsible for nearly all the animal data in this chapter. His 
nearly single-handed management of the legions of mice involved in these multi-month-
long studies is both admirable and impressive and deserves special recognition and 
appreciation. I am truly grateful for his efforts. 
4.2 Introduction 
Malignant mesothelioma is an aggressive cancer of the mesothelial cells that line 
the thoracic and abdominal cavities, frequently resulting from exposure to asbestos with a 
20-30 year latency period. Currently, there is no curative therapy and the median 
. 1 . h . . . nl 4 12 h 48 so 200-201 Unl"k surv1va , w1t out mterventwn, IS o y - mont s. ' ' 1 e most cancers, 
mesothelioma is highly localized to the pleural (i.e., thoracic) or peritoneal 
(i.e. , abdominal) cavities with patients succumbing to locoregionally recurrent, as 
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opposed to metastatic, disease. Massivectumor bulk, pleural effusions and/or ascites due 
to diffuse peritoneal or pleural implants make mesothelioma difficult to treat and result in 
poor quality of life and an overall 5-year survival rate of only 10-15%. 54• 202-209 
4.2.1 Paclitaxel Use in Malignant Mesothelioma 
Among traditional chemotherapeutics, paclitaxel (Pax) based therapies are not 
commonly used for mesothelioma because poor response to systemic Pax therapy has 
resulted in designation of mesothelioma as a "Pax-resistant" tumor. Furthermore, a recent 
Phase III clinical trial demonstrated that intravenously (IV) administered pemetrexed + 
cisplatin provided the most significant increase in patient survival to date, thereby 
making this therapy the preferred regimen? 10 However, three important factors must be 
considered. The first is that the improvement in patient survival, while significant, was 
nevertheless a modest 2.8 months (from 9.3 to 12.1) indicating that this combination 
therapy is merely an incremental advance. The second consideration is that the 
chemotherapy was administered IV, i.e., systemically, where minimal drug reaches the 
tumor tissue, particularly intraperitoneally or intrapleurally. Third, several in~estigators 
have shown that when Pax is given locally, marked responses to prevent mesothelioma 
recurrence are possible. 
In contrast to the modest improvements seen in this trial, significant 
improvements in patient outcome have been seen in a subset of qualifying patients with 
intraperitoneal mesothelioma treated with multi-modality approaches involving 
cytoreductive surgery m combination with hyperthermic intraperitoneal (IP) 
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perioperative chemotherapy (HIPEC).Z 11 -215 A leading surgical oncologists operating on 
mesothelioma patients, P.H. Sugarbaker, has used multi-modality combination therapy 
(early post-operative intraperitoneal chemotherapy; EPIC) that includes IP administered 
Pax to significantly improve patient outcomes (59% and 39% overall survival at 5- and 7-
years following diagnosis-a remarkable outcome given the rapid progression and death 
f . . h h 1" . h" 2 3 f d" . ) 216-217 0 "bl o most patients w1t mesot e wma w1t m - years o mgnos1s . ne poss1 e 
explanation for this improved outcome is the benefit gained by IP administration of Pax. 
As one of the largest chemotherapeutic drugs (molecular weight (MW) = 853.9), Pax's 
clearance from the IP space is at least an order of magnitude slower (area under the curve 
(AUC) = 1000) than smaller agents such as cisplatin (MW = 300.1 , AUC = 7.8) or 
pemetrexed (MW = 597.49, AUC = 40.8) thereby resulting in longer IP dwell times and, 
thus, increased contact with and penetration into unresected established tumor tissue.218-
220 Given these clinical data, we hypothesized that a drug delivery system that can further 
increase target tissue specificity and duration of intratumoral residence time by yet 
another order of magnitude may provide significantly improved outcomes and/or durable 
cures. 
4.2.2 Drug Delivery Systems for Hydrophobic Chemotherapeutics 
A key feature of micro- and nanoparticle (NP) drug delivery systems is their 
ability to improve the effective solubility of hydrophobic drugs via encapsulation within a 
hydrophobic polymeric core and to deliver higher drug concentrations to target sites. In 
so doing, the disadvantages of these poorly water-soluble, hydrophobic agents, such as 
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Pax, become valuable attributes wherein slow or triggered drug release from the delivery 
system is made possible due to the highly favorable hydrophobic-hydrophobic 
. . b h d d . 121 , 125 221 I . "bl 1 . .1 mteractwns etween t e rug an earner. ' t 1s not poss1 e to everage s1m1 ar 
interactions with hydrophilic drugs (such as pemetrexed or cisplatin) because their water 
solubility results in rapid diffusion out-of/away-from a delivery vehicle. One solution to 
this problem is the conjugation of hydrophilic drugs to components of the delivery 
device; however, this results in creation, from a regulatory viewpoint, of an entirely new 
d . . 1 h . . d 1" . 1 222-223 Th rug requmng comp ete c aractenzatwn an c 1mca assessment. us, a tumor 
specific drug delivery system that non-covalently encapsulates chemotherapeutic agents 
will be most suited to the delivery of hydrophobic agents. For this reason, in combination 
with clinical data demonstrating the positive impact of Pax in some patient populations, 
we have chosen Pax as a therapeutic for mesothelioma. 
4.2.3 Nanoparticle Mediated Drug Delivery Promises Advantages Over Current Routes 
of Administration 
The use of ffilcro- and nanoparticles can address many of the difficulties 
encountered when administering therapeutic compounds by increasing the solubility of 
hydrophobic drugs, providing more consistent drug levels through sustained release, 
protecting sensitive drugs from low pH environments or enzymatic alteration, and, in 
"d" 1 1 d 1" d . d . d . 117 119 224-229 some cases, prov1 mg oca e 1very or rug targetmg to a esue t1ssue. ' ' 
Increased stability and the ability to adjust delivery properties by manipulation of 
structure and composition suggests that polymeric NPs may be particularly well suited 
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for delivering chemotherapeutic agents in a post-operative setting. Several drug delivery 
systems using micro-/nanoparticles, nanorods, micelles, or hydrogels, have been 
. . . 130 221 230-232 developed specifically for the treatment of pentoneal carcmomatoses. ' ' 
Although several natural and synthetic polymers have been investigated (including 
chitosan,233 methacrylic acid copolymers,234 and polycaprolactone235) , poly(lactic acid) 
(PLA) and poly(lactic-ca-glycolic acid) (PLGA) are the most widely studied due to 
availability, biocompatibility, and use in other FDA approved devices. They are, 
however, less appropriate for intraoperative or early post-operative administration (when 
healing is a primary concern) due to the relatively rapid "burst" release of >50% of 
encapsulated drug in the first 10-48 hr that occurs regardless of NP proximity to 
128 236-237 I fun . 1 h dr d 1' b '1 d tumor. ' n contrast, ctlona systems w ere ug e Ivery can e tal ore to 
and even triggered by specific physical stimuli (e.g., pH, temperature, oxidative/reductive 
environments, osmolality increases/decreases) are being pursued to improve anti-tumor 
f 'C: 135, 221 , 238-241 e JJcacy. 
In this study, we use a pH-responsive expansile nanoparticle (eNP) delivery 
system to increase the efficacy of IP administered Pax in treating established peritoneal 
mesothelioma. The eNP delivery system possesses two unique characteristics: 1) tumor 
specific localization and entrapment; and 2) a triggered physiological pH transition that 
results in intracellular swelling of the particle and subsequent slow drug release within 
tumor cells to provide high, prolonged tumor-tissue drug concentrations (Fig. 4.1 ). 
Results from a previous study investigating these Pax-loaded eNPs (Pax-eNPs) resulted 
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in three observations that guided the present work: 1) despite superiority in vivo, Pax-
eNPs were less effective than free Pax (i.e., ICso = 38.5 ng/mL v. 6.56 ng/mL, 
respectively) in traditional in vitro cytotoxicity studies against a human mesothelioma 
cancer line (MST0-211H); 2) in a murine model of established IP mesothelioma, 
fluorescently labeled eNPs exhibited tumor-specific localization 72 hr following IP 
injection; and, 3) in a prevention of establishment disease model, a single IP injection of 
Pax-eNPs significantly reduced tumor burden compared to IP treatment with the standard 
clinical formulation of Pax solubilized in Cremophor/ethanol (Pax-C/E) and improved 
overall animal survival (54 v. 39 days, respectively). 109 
In this manuscript, we build off these observations and extend this work as 
follows. First, the paradoxical outcome of Pax-eNP vs. Pax-C/E performance in vitro vs. 
in vivo was thought to result from a lack of drug metabolism and clearance in vitro 
prompting the design of a short-duration treatment-exposure model to better mimic in 
vivo pharmacokinetics in vitro. Second, the kinetics of eNP localization to IP tumors was 
investigated both as a function of time and as related to eNP internalization in healthy 
and malignant peritoneal cell lines in vitro. Third, it is well known that cell-cycle-specific 
chemotherapeutics (e.g., Pax) are most effective when high target concentrations are 
maintained over multiple cell cycles while low drug concentrations may actually prove 
detrimental by facilitating the selection and growth of cancer stem cells?42-243 In an 
attempt to achieve and maintain high tumor concentrations while minimizing systemic 
toxicity and side effects, multiple-dose Pax-C/E regimens are used clinically. We 
hypothesized that a multiple-dose regimen of Pax-eNPs would deliver significantly more 
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Pax into IP tumors than Pax-C/E and therefore result in improved outcomes. To test this 
hypothesis, we used three models of multiple-dose treatments ( 4 weeks, standard dose-
10 mg/kg/wk; 4 weeks, high dose-20 mg/kg/wk; 8 weeks, standard dose-
10 mg/kg/wk) to investigate the effect of drug dose and duration on overall survival. 
4.3 Materials and methods 
4. 3.1 Nanoparticle Synthesis 
Expansile nanoparticles (eNPs), paclitaxel-loaded eNPs (Pax-eNPs), poly(lactic-
co-glycolic) acid (MW ~50-80k) nanoparticles (PLGA-NPs), and paclitaxel-loaded 
PLGA-NPs (Pax-PLGA-NPs) were prepared using a previously reported mini-emulsion 
hni 'th b 1 d 1 . . f NP 108-109 244 Th 1 . tee que w1 ase-cata yze po ymenzat10n o e s. ' e encapsu at10n 
efficiency of paclitaxel (Pax) was determined by adding 50 ).!L of Pax-NPs to 950 ).!L of 
acetonitrile, filtering to remove precipitated polymer, and quantifYing Pax concentration 
by high performance liquid chromatography (HPLC) using a previously reported 
hni 245 tee que. 
Fluorescently labeled eNPs were prepared by incorporating 0.02% (w/w) 
PolyFluor™ 407 (9-anthracenylmethyl methacrylate; PF-eNPs) or PolyFluor™ 570 
(methacry1oxyethyl tricarbonyl rhodamine B; Rho-eNPs), respectively, into the polymer 
backbone during polymerization. 
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4.3.2 Cell Lines 
Human malignant pleural mesothelioma cells (MST0-211H), firefly luciferase 
gene transfected MST0-211H cells (MST0-211H-Luc; a generous gift from J. 
Rheinwald at Harvard Medical School, Boston, MA), and healthy mesothelial cells (LP-
3) were maintained at 37 °C in 5% C02 in complete media (CM) using RPMI 1640 or 
DMEM media, respectively, containing 10% (v/v) fetal bovine serum, streptomycin (100 
mg/mL), and penicillin (100 units/mL). 
4. 3. 3 In Vitro Cell Viability 
MST0-211H tumor cells were seeded in 96-well plates at 2,000 cells/well in 
CM. After 24 hr, media was removed and replaced with CM containing Pax-eNPs, 
unloaded-eNPs, or Pax-C/E-equivalent Pax doses were determined based on 
encapsulation efficiency. Cells were incubated with treatments for 4 hr, treatments were 
removed, and cells washed thrice with warm phosphate buffered saline (PBS) before 
addition of CM without treatments. After further culturing for 3 d, cell viability was 
determined using the CellTiter 96® Aqueous One Solution Cell Proliferation Assay 
(MTS). All viability assays were performed in triplicate and the percent viability of 
treatment wells was calculated as absorbance relative to control wells receiving no 
treatments. Data are presented as mean ± standard deviation. 
4. 3. 4 In Vivo Tumor Model 
All animal studies utilized a murine model of established mesothelioma. Briefly, 
6-8 week old, female, athymic, nude (Nu/J) mice were purchased from Jackson 
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Laboratory and housed under sterile conditions. Animal care and procedures were 
conducted with the approval of the Institutional Animal Care and Use Committee, in 
strict compliance with all federal and institutional guidelines for the care and use of 
laboratory animals. Mice received an intraperitoneal (IP) injection of 5 x 106 MST0-
211H or MST0-211H-Luc cells yielding established tumors within 7-10 d of 
xenografting. 
4.3.5 In Vivo Localization ofeNPs to Tumors 
Seven days after xenografting, animals received an IP injection of 250 mg/kg 
fluorescently labeled PF-eNPs diluted to 300 f.lL with saline. At time points of 1 hr, 4 hr, 
24 hr, 72 hr, and 14 days following PF-eNP injection, bioluminescent imaging (BLI) was 
performed, with mice receiving an IP injection of 2.25 mg firefly luciferin prior to 
imaging with a Xenogen IVIS-50 bioluminescence camera using a 10 s exposure time. 
Animals were then sacrificed and high-resolution digital photographs were taken of the 
IP space using a Canon PowerShot A640 camera under ambient and ultraviolet (254 nm) 
light from a Wood' s lamp. 
4.3.6 Quantification ofeNP Uptake in Vitro by Flow Cytometry 
Flow cytometry was used to quantify the cellular uptake of Rho-eNPs in MST0-
211H human mesothelioma tumor cells and in healthy LP-3 mesothelial cells. Cells were 
seeded in 6-well plates at 200,000 cells/well in CM and allowed to adhere and grow for 
24 hr. The media was removed and replaced with 2 mL of media containing 50 f.lg/mL 
Rho-eNPs (polymer concentration) and the cells incubated for 0 hr, 2 hr, 8 hr, or 24 hr. 
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At each time point, the media was removed, the cells washed 3X with PBS, and fixed in 
4% formaldehyde prior to analysis using a Beckman-Coulter MoFlo high-speed cell 
analyzer/sorter. 
4.3. 7 Autophagosomal Accumulation in eNP Treated Cells 
MST0-211H cells were cultured on glass coverslips for 24 hr before treatment 
with media (negative control) 25 ~-tM chloroquine (positive control) Rho-eNPs (25 ~-tg/mL 
experimental), or Rho-eNPs plus secondary Ab for LC3 (secondary Ab-eNP interaction 
control). After a further 24 hr incubation, cells were washed 2X with phosphate buffered 
saline (PBS), before staining the cell nucleus (Hoeschst), cell wall (wheat germ 
agglutinin 633) and LC3 (LC3-anti rabbit; rabbit-FITC), a protein that is naturally turned-
over in the autophagosome but is shown to accumulate within dysfunctional 
autophagosomes associated with pathological states (e.g., fatty liver, diabetes). 
4.3.8 Multiple-Dose Models Treating Established Disease 
In the first four-dose study, animals received four weekly treatments of Pax-eNPs, 
eNPs, Pax-PLGA-NPs, PLGA-NPs, Pax-C/E or saline. All Pax treatments were given as 
IP injections at an equivalent dose of 10 mg/kg/week (~250 11g Pax/injection) every week 
for four weeks. Long-term survival was assessed in animals with daily follow-up and 
individual sacrifice upon evidence of morbid disease progression. In the follow-up high-
dose-four week study, animals received injections of Pax-eNPs, eNPs, or Pax-C/E using 
the same weekly treatment schedule but with an equivalent Pax dose of 20 mg/kg/week 
each week for four weeks. Lastly, in an eight-dose study, animals received weekly 
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injections ofPax-eNPs, eNPs, or Pax-C/E using a Pax equivalent dose of 10 mg/kg/week 
each week for eight weeks (again, 2 mg total Pax dose). All injections were in a 300 IlL 
volume. 
4. 3. 9 Paclitaxel Tissue Concentration 
Two weeks following xenografting, animals received IP injections of Pax-eNPs, 
Pax-C/E, or Pax-PLGA-NPs (10 mg/kg). Three days following injection, animals were 
sacrificed in a blinded fashion as to treatment received and all visible tumor harvested. 
Pax tissue concentrations were measured by Apredica Inc. using HPLC. Briefly, Pax was 
extracted from the tissue using an acetonitrile incubation for 30 min followed by 
centrifugation for 5 min at 14k RPM to remove precipitate. The supernatant was analyzed 
by LC/MS/MS using an Agilent 641 0 mass spectrometer coupled with an Agilent 1200 
HPLC and a CTC PAL chilled autosampler, all controlled by MassHunter software. After 
separation on a C18 reverse phase HPLC column using an acetonitrile-water gradient 
system, peaks were analyzed by mass spectrometry (MS) using ESI ionization in MRM 
mode. The limit of detection was 13.5 ng/g tissue. 
4. 3.10 Statistics 
Data are presented as mean ± standard deviation unless specified in the text. All 
computations were done in SAS v9.2 for Unix or Prism 6.0 software. All significance 
tests and quoted P-values are two-sided with P < 0.05 as significant. 
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4.4 Results 
Expansile nanoparticles (eNPs), paclitaxel-loaded eNPs (Pax-eNPs), poly(lactic-
co-glycolic) acid (MW ~50-80k) nanoparticles (PLGA-NPs), and paclitaxel-loaded 
PLGA-NPs (Pax-PLGA-NPs) were prepared using a previously reported mini-emulsion 
hn. . h b 1 d 1 . . f NP 108-109 244 p . d' h tee 1que w1t ase-cata yze po ymenzatwn o e s. ' revwus stu 1es ave 
demonstrated that these particles are 20-200 nm in diameter with spherical morphology 
and that eNPs expand at mildly acidic pH ( ~5), such as that found within the cellular 
endosome, to release their encapsulated drug in a pH- and time-dependent manner. 108-110• 
244 The encapsulation efficiency of paclitaxel (Pax) in eNPs loaded with 5% Pax by 
weight, as determined by HPLC, was in agreement with previous studies at 2:80% for all 
particle formulations. 
4. 4.1 Nanoparticle Cytotoxicity in Vitro 
MST0-211H cells were exposed to Pax-eNPs, eNPs (vehicle control), or Pax-C/E 
(clinical formulation control) for 4 hr to simulate the in vivo scenario of fast clearance 
and short effective drug exposure time in vivo. After washing off treatments and culturing 
cells for a further three days before assessing cell viability, treatment with Pax-eNPs 
yielded an IC5o = 44.6 ng/mL while Pax-C/E yielded an IC5o = 1009 ng/mL (P < 0.01) 
(Fig. 4.2). Compared to continuous treatment for three days, Pax-C/E demonstrated a 
remarkable shift in IC5o, increasing over 153-fold while the IC5o of Pax-eNPs was nearly 
the same (increased only 1.15-fold). These results demonstrate that with limited exposure 
time endocytosis of Pax-eNPs and subsequent slow intra-tumor Pax release is markedly 
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superior to brief exposure of solubilized Pax as likely occurs in vivo (i.e., >90% of Pax is 
cleared from the IP space after 6 hr and less than 1% of the injected dose remains at 24 
hr220, 246). 
4. 4. 2 Kinetics of eNP Tumor Co-Localization 
5 x 106 MST0-211H-luc cells were injected 7 d prior to the IP injection of 
fluorescent PF -eNPs, which emit a strong visible light signal under ultra-violet (UV) 
(254 nm) excitation. Prior to sacrifice, tumor location was identified by bioluminescent 
imaging (BLI) followed by euthanasia and necropsy. Gross examination of the IP space 
under visible light confirmed tumor location and imaging with a hand-held UV (Wood' s) 
lamp identified the location of PF -eNPs. The location of the BLI signal matched the 
visible tumor tissues, and strong co-localization between PF-eNPs and both large and 
small tumor nodules was observed within 1-4 hr of injection with co-localization 
persisting for 14 d (Fig. 4.3). Furthermore, the organs of the reticuloendothelial system 
(RES) (e.g. , liver, spleen, kidneys) showed no overt sign of eNP accumulation. Note that 
the slight, light blue background signal seen across all animals is not PF -eNP 
accumulation on every surface but, rather, auto fluorescence due to the UV light as 
evidenced by the same blue background on the outside of the skin flaps and feet (which 
were never exposed to the PF-eNPs). 
4. 4. 3 Nanoparticle Uptake in Healthy and Malignant Cells 
Normal human mesothelial cells (LP-3) and the malignant human mesothelioma 
cells (MST0-211H) were exposed to Rho-eNPs for 0 hr (control), 2 hr, 8 hr, or 24 hr 
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before being washed and analyzed by flow cytometry. The MST0-211H cells exhibited 
rapid uptake of Rho-eNPs with >98% of cells showing Rho-eNP internalization within 
2 hr (Fig. 3.4). In contrast LP-3 uptake of Rho-eNPs was an order of magnitude slower 
with only 28% showing internalization at 8 hr, increasing to >90% only after constant 
exposure for 24 hr, something that is less likely to occur in vivo especially given the 
selective uptake of nearby cancer cells. 
4. 4. 4 eNP Induced Autophagosomal Accumulation 
LC3 is a cytosolic protein that is turned over and recycled in the autophagosome. 
In several pathological states (e.g. , high fat diets or diabetes) LC3 accumulates in 
dysfunctional autophagosomes and, as a result, can be used to track autophagosomal 
accumulation within cells. MST0-211H cells treated with Rho-eNPs for 24 hr exhibited 
accumulation of LC3 protein in bright, punctate dots co-localized with the Rho-eNP 
signal (Fig. 3.5). LC3 distribution was similar to that of the positive (chloroquine 
treatment) control while the negative (media) control exhibited slight, non-specific 
background LC3 signal. Non-specific binding between the secondary LC3-Ab and Rho-
eNPs was not observed. 
4. 4. 5 Survival Study 
This study used a model of established mesothelioma in which the fust treatments 
are administered seven days following xenografting, at which point established tumors 
are present. Mice treated with 4 weekly doses of Pax (10 mg/kg) in different formulations 
including: Pax-eNPs (experimental; n = 12), Pax-PLGA-NPs (generic NP control; n = 
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12), Pax-C/E (clinical formulation control; n = 12) as well as the respective unloaded 
particle controls (i.e. , eNPs, PLGA-NPs; n = 6 for both), and saline (tumor growth 
control; n = 6). Pax treatment in all three formulations improved survival compared to the 
saline control group (median survival 38 days; all three Pax formulations individually 
compared to saline, P < 0.05) (Fig. 4.6A). When comparing the three different 
formulations of Pax, Pax-eNP treatments resulted in the longest overall survival with a 
media of 74 d compared to either Pax-PLGA-NPs or Pax-C/E (43 d and 46 d, 
respectively, P < 0.05). Pax-PLGA-NP treatments showed no significant difference in 
survival compared to the same dose of Pax-C/E (P = 0.1459). The unloaded-eNP and 
unloaded-PLGA-NP groups had a median survival of 37 days and 30 days, similar to the 
saline control group. 
Given the significant benefit to animal survival observed with Pax-eNP treatment 
in the previous study, we hypothesized that doubling the weekly dose would provide still 
further improvement in disease control and, subsequently, overall survival. Thus, this 
study was repeated with Pax treatments of 20 mg/kg given on the same weekly four-dose 
schedule. Because treatment with Pax-PLGA-NPs showed no improvement compared to 
Pax-C/E in the previous study, it was not included as a treatment group. Despite a 
doubled weekly dose of Pax (20 mg/kg), median survival in the Pax-eNP (n = 11) and 
Pax-C/E (n = 11) treatment groups was 64 d and 36 d, respectively (Fig. 4.6B). This 
surprising result (i.e. , no improvement in overall survival by doubling the weekly dose) 
suggested that the treatment failure in both this and the previous study was due, not to the 
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static concentrations of drug at any one time, but rather, to the kinetics of tumoral drug 
concentrations. 
To address this hypothesis, we repeated the study again, usrng the original 
10 mg/kg dose while extending the duration of treatment an additional four weeks (i .e., 
eight weeks-treated twice as long as the first study). Doubling the duration (and 
number) of treatments at a low dose resulted in significantly increased median overall 
survival of 103 d for the Pax-eNP group (n = 12) vs. 49 d for the Pax-C/E group (n = 12; 
P < 0.01 ) (Fig. 4.6C), and was markedly superior to the same total Pax dose given over 
half the time. Interestingly, the period of time between the last treatment and the median 
overall survival was remarkably similar between the four- and eight-dose studies at 36 
and 37 days, respectively. 
4.4.5 Paclitaxel Concentration in Tumors 
Tumors were allowed to grow for two weeks prior to IP injection of Pax-eNPs, 
Pax-PLGA-NPs or Pax-C/E (10 mg/kg for all treatments). Tumors were harvested three 
days after treatment, weighed, and Pax quantified by HPLC. The average tumor weights 
for all three groups were not statistically different (217 mg, 588 mg, and 488 mg from 
mice assigned for Pax-eNP, Pax-PLGA-NP, and Pax-C/E, respectively, P > 0.05). One 
mouse in the Pax-PLGA-NP group and one mouse in the Pax-C/E group were excluded 
due to absence of visible tumor to harvest, but concentrations and total dose were 
calculated accordingly. The tumoral concentration of Pax was significantly higher in Pax-
eNP treated mice than in Pax-PLGA-NP treated mice and Pax-C/E treated mice (37.6 ± 
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6.7 f.lg/g vs. 13.8 ± 4.5 f.lg/g and 0.37 ± 0.09 f.lg/g, both P < 0.05) (Fig. 4.7). There was no 
statistical difference in the tumoral concentration of Pax between Pax-PLGA-NPs and 
Pax-C/E. The total Pax in tumor tissue followed a similar trend as the drug concentration 
in which 20% ofthe Pax-eNP, 6% the Pax-PLGA-NP, and <0.1% ofthe Pax-C/E injected 
dose (ID) remained in the tumor tissue three days following treatment. 
4.5 Discussion 
Over the last decade, the experimental approaches to improve clinical outcomes in 
intraperitoneal (IP) malignancies (e.g., mesothelioma, ovarian cancer) have evolved to 
include administration of chemotherapeutic agents. IP therapy offers several advantages 
over the traditional intravenous (IV) route of administration including: direct exposure of 
tumors to chemotherapy, high and prolonged (relative to IV administration) intratumoral 
drug concentrations, and minimized systemic side effects. While local toxicity and 
complications from indwelling catheters must be monitored and managed carefully, the 
clear benefits to overall patient survival have rendered this a standard and frequently used 
therapy for these deadly and debilitating peritoneal malignancies. 
While a recent study demonstrating the statistically significant benefit to 
mesothelioma patients from IV combination pemetrexed and cisplatin has garnered 
significant attention, the incremental nature ofthis advance suggests that other paradigm-
shifting strategies must be employed. However, due to the relatively small number of 
patients afflicted with this disease, there is limited prospective, controlled, clinical trial 
data regarding the routes, methods and combinations of chemotherapy used in IP 
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mesothelioma. Clinical observations with HIPEC demonstrate that the use of IP Pax can 
assist in providing long-term survival benefit in some patients. These results are likely 
related to the relatively favorable pharmacokinetics of IP administered Pax as compared 
to other small-molecule agents (i.e., reduced rates of clearance and significantly longer IP 
dwell times). Nevertheless, Pax is cleared from the IP space within 24 hr.220' 246 We 
hypothesize this limitation is responsible for the suboptimal efficacy of Pax and that 
methods and devices which increase IP and intratumoral drug residence times will 
provide improved outcomes. 
Limiting factors in current clinical formulations of Pax include: the 
pharmacologic properties of the peritoneal plasma barrier, the rate of drug clearance, and 
extent of tissue penetration, which depends on the IP concentration, time of exposure, 
molecular weight, lipophilicity, and temperature of the carrier solution.247 In the specific 
case of the clinical formulation of Pax-C/E, the in vivo volume of biodistribution of C/E 
is significantly lower than for Pax indicating that C/E is not readily taken up into tissues. 
Hence intracellular tissue concentrations of Pax may be limited by the very excipient 
used to solubilize it for administration?48 Thus, the utility of prolonged IP Pax delivery 
via C/E is questionable, as Pax is entrapped in the C/E micelles lowering its 
b. '1 b'l' 220 wavm a 1 1ty to tumors. 
Several studies have examined methods for increasing IP dwell times of Pax. 
Mohamed et al. compared IP administration of Pax in a 1.5% dextrose peritoneal dialysis 
solution and in a high MW 6% hydroxyethyl hetastarch solution.219 While the hetastarch 
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maintained higher IP Pax concentrations 12 hr after injection, no significant difference 
was measured at the 24 hr time point. Tsai et al. compared IP dwell times of Pax 
administered in one of three formulations: C/E, gelatin nanoparticles, or PLGA-
microparticles. The gelatin and C/E formulations resulted in rapid clearance from the IP 
space (<1% of the injected dose remaining 24 hr post injection) while PLGA-
microparticles prolonged the IP dwell time of Pax. Nevertheless, even the PLGA-
microparticle formulation failed to achieve significant long-term advantages with <2.5% 
of the injected dose remaining after 72 hr, a value even lower than found with Pax-
PLGA-NPs in our studies and well below the 20% remaining with Pax-eNPs. Results of 
these studies demonstrate that, despite the inherent advantages of using Pax in IP therapy 
(i.e., large MW and slow clearance by diffusion alone) and despite numerous attempts to 
increase IP dwell times, there is still a significant need for improvement. 
We aim to improve the delivery of Pax to IP mesothelioma via encapsulation in 
our eNP delivery system. First, we addressed the difficulty of designing accurate and 
effective in vitro experiments to predict and optimize in vivo dosing and treatment 
regimens-a well documented challenge.249 Traditional in vitro assays fail to accurately 
model complicating in vivo factors such as drug degradation, clearance, and 
biodistribution. Furthermore, traditional in vitro assays evaluate cell viability 
immediately after exposure to treatments therein masking their longer term delayed 
effects; this is particularly confounding with cell-cycle specific drugs, such as Pax, which 
require several cell cycles to induce apoptosis. In a series of studies examining the 
immediate and delayed cytotoxic effects of Pax, Au et al. demonstrated the importance of 
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the duration of Pax exposure to its effectiveness in vitro?49 When a panel of six cancer 
cell lines was treated for a short duration of 3 hr, washed clean and then incubated for 
four days before assessment of cell viability, the ICso was 10- to 40-fold greater (i.e., less 
effective) than when cells were exposed to treatments for the entire duration of the four 
day assay. 249 These findings are similar to those found in our 4 hr assay where such a 
decrease in efficacy (i.e., increased IC50) was not noted to occur with Pax-eNP. 
Thus, we designed a similar in vitro assay to account for both the short duration of 
exposure in vivo and the delayed effects of Pax. Cells were treated for 4 hr with either 
Pax-eNPs, eNPs, or Pax-C/E washed and cultured for a further three days prior to 
analysis of cell viability. In this short-duration assay, Pax-eNPs performed significantly 
better (22-fold lower IC50) than Pax-C/E confirming our hypothesis that short drug 
exposure time in vivo is one of the reasons Pax-eNP treatments are more effective than 
Pax-C/E. This is the first time that our in vitro data support our previous (and current) in 
vivo data. 
Pax-eNP effectiveness after only a 4 hr exposure in vitro alludes to the rapid 
internalization of eNPs within tumor cells, an effect further studied in vivo. We probed 
the kinetics and duration of eNP localization to IP tumors in vivo using fluorescent PF-
eNPs. The results clearly demonstrate that, even with natural variations in tumor burden 
and distribution, and the fact that fluorescence provides a qualitative assessment of eNP 
location, eNP localization to tumors occurs rapidly within 1-4 hr of injection and persists 
for at least two weeks. Importantly, no overt particle accumulation was observed in 
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organs of the reticuloendothelial system (e.g., liver, spleen, kidneys). Other researchers 
have investigated the localization of polymeric PLGA-microparticles to ovarian 
250 tumors, but no data is available in peritoneal mesothelioma models. Within the 
ovarian study, differences in material type (eNP v. PLGA), particle size (20-200 nrn v. 4-
30 J..Lm), surface charge (-46 mV v. unreported, but likely ~0 mV due to polyvinyl alcohol 
surfactant), and pathophysiology (mesothelioma v. ovarian cancer) make comparisons to 
the current study impractical. Nevertheless, the current data provide compelling evidence 
for the tumor-specific localization of eNPs without the need for targeting agents or 
moieties and highlight the rapid kinetics (1-4 hr) and prolonged retention (14 days) 
within tumors. 
We hypothesized that the mechanism behind eNP affmity to tumors is related to 
rates of endocytosis in malignant and healthy cells. This hypothesis originated from a 
recent study using pharmacologic inhibitors to demonstrate that rapid eNP uptake in 
MDA-MB-231 breast cancer cells occurs primarily through non-specific, receptor-
. d d th . . . 245 I h d f1 · m epen ent pa ways via macropmocytos1s. n t e current stu y, ow cytometnc 
analyses showed that eNP internalization in healthy mesothelial cells (LP-3) occurs an 
order of magnitude slower than in malignant mesothelioma cells (MST0-211H). While 
other factors may play a role in this process, this study confirms that the rate of particle 
internalization is one of the mechanistic components responsible for eNP tumor-specific 
localization. Further studies probing this mechanism will involve competitive uptake 
assays using co-culture of healthy (e.g., LP-3), malignant (e.g., MST0-211H), and 
stromal (e.g., 3T3-mouse fibroblast, and RAW-mouse macrophage) cells using three-
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dimensional spheroid models of tumors embedded in collagen matrices to more 
effectively recapitulate the tumor microenvironment and spatial orientation (2D vs. 3D). 
Such work is beyond the scope of this study but will be performed using our recently 
developed and published tumor spheroid models.251 
The results of the LC3 protein accumulation study suggest that retention of eNPs 
may be related to the intracellular accumulation of autophagosomes, which itself may be 
induced by eNPs. Treating cells with chloroquine results in pharmacologic inhibition of 
autophagic flux. This inhibition leads to decreased protein degradation and turnover 
resulting in build-up of proteins, including LC3 (microtubule associated protein lA/lB 
light chain 3). During autophagy, phosphatidylethanolarnine is conjugated to cytosolic 
LC3 (i.e., LC3-I) to form LC3-II, which is sequestered in autophagosome membranes. 
Thus, LC3-II accumulation can serve as a surrogate marker for autophagosome 
accumulation. eNP treatment of MST0-211H cells resulted in a similar distribution 
pattern of punctate LC3-II fluorescence strongly co-localized with the fluorescent (i.e., 
rhodamine) signal of the eNPs. All relevant negative and secondary Ab controls showed 
no punctate accumulation of LC3-II. The specific mechanism behind the inhibition of 
autophagic flux will be the subject of further study; however, it is likely that this inability 
to removed particles is at least partially responsible for the long-term accumulation of 
eNPs in tumors in vivo. 
Three survival studies demonstrate the importance of both the method of delivery 
and treatment-schedule in maximizing a Pax's therapeutic effect. In a murine treatment-
of-established disease model, all Pax treatment groups exhibited statistically significant 
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increases in survival compared to the saline control (P < 0.05). This reflects the clinically 
observed results that multiple cycles of IP Pax assist in providing an overall survival 
benefit compared to treatment without IP therapy. The Pax-eNP formulation 
distinguished itself from the C/E and PLGA-NP formulations with a significantly longer 
median overall survival (74 d vs. 43 and 46 d, respectively) and with 33% of the animals 
demonstrating a complete response at 90 days. The success of Pax-eNPs and failure of 
Pax-PLGA-NP treatments to improve survival compared to Pax-C/E demonstrates the 
importance of material composition in designing particle-based drug delivery devices. In 
particular, tumor-localized eNPs release Pax to become bio-available only once localized 
to the tumor tissue. In contrast, the rapid, un-triggered, and non-specific release of Pax 
from PLGA-NPs within 12-24 hr of administration is likely a critical factor in their 
inability to improve overall survival in the current study. 128 
We hypothesized that the benefit to overall survival achieved using Pax-eNPs in 
this four-dose model could be amplified by increasing the dose from 10 mg/kg/wk to 
20 mg/kg/wk-a dose still within a clinically acceptable range. Interestingly, the median 
survival for Pax-eNP and Pax-C/E treated animals was 64 d and 36 d, respectively. It is 
clear that doubling the drug dose provided little or no benefit to overall survival. This 
result highlights the importance of maintaining therapeutic concentrations of Pax within 
the target tissue over time scales that span not only several days, but also several 
weeks/months. Doubling the weekly dose did not provide sufficient drug to eliminate the 
tumor or inhibit growth to a greater extent than the 10 mg/kg treatment and, hence, when 
treatments ended, the residual disease progressed. 
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In contrast, the eight-week dosing study using the standard 10 mg/kg/wk resulted 
in median overall survival of 103 d and 49 d for Pax-eNP and Pax-C/E treated animals, 
respectively. All but one of the animals receiving Pax-C/E treatments died before 
completing their 8-dose regimen reflecting the ultimate clinical futility of treating 
established disease with only current clinical formulations of IP chemotherapy. This 
would also be consistent with the clinical assessment of mesothelioma as Pax-resistant. 
Interestingly, for animals in the Pax-eNP group, the time from final treatment to median 
overall survival was 46 d for those receiving 4 weeks of 10 mg/kg Pax and 4 7 d for those 
receiving 8 weeks of 10 mg/kg Pax. However, despite this similar duration from end-of-
treatment to median survival, animals in the 4-week group died primarily of bulky, 
established tumor while those in the 8-week group died: 1) bearing small tumors; and/or, 
2) with large volumes of ascites. These differences in disease-state at the time of death 
suggest that Pax-eNPs have shifted the pathological mechanisms resulting in animal 
mortality away from the traditionally observed problem of locally recurrent bulky 
disease. 
Furthermore, judicious application of the same total quantity of Pax (2 mg) was 
used to best effect as a prolonged (8 week) as opposed to acute (4 week) therapy. 
Importantly, taken on their own, the poor results from the Pax-C/E treatments serve to 
further the idea that mesothelioma tends to be Pax "resistant". However, the results from 
the Pax-eNP treatments reveal that if delivered properly, Pax can effectively manage this 
disease. Multiple injections of responsive, controlled-release Pax-eNPs are effective in 
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prolonging overall survival in vivo, even in a traditionally "paclitaxel-resistant" tumor 
model, due to the improvement of drug exposure patterns. 
To probe the underlying mechanism behind Pax-eNP efficacy in vivo, we 
quantified the intratumoral concentrations of Pax three days following an IP injection of 
10 mg/kg Pax-eNPs, Pax-C/E or Pax-PLGA-NPs. The eNPs afforded over 100-fold 
greater intratumoral Pax concentrations than Pax-C/E. Given the importance of 
concentration and duration of exposure to the effectiveness of Pax, this two order-of-
magnitude increase explains the significantly improved overall survival metrics of Pax-
eNPs compared to Pax-C/E. Furthermore, in comparing Pax-eNPs to Pax-PLGA-NPs, 
eNPs exhibited ~5-fold higher tumor concentrations of Pax. 
Tumor drug levels have been evaluated in other cancers, such as ovarian cancer, 
that were treated using a particle-based drug delivery system. PLGA-microparticles 
(previously noted to localize to IP ovarian tumors) were designed to deliver Pax with a 
two-phase release profile to afford both high initial and prolonged cytotoxic 
concentrations?50 Seventy-two hours after an IP injection of these Pax-loaded PLGA-
micropruiicles, Pax concentrations within the tumor were 13,000 ng/g. These tumor 
concentrations, which are ~10-fold lower than those achieved with Pax-eNPs in the 
current study, are in general agreement with those observed in this study using Pax-
PLGA-NPs (i.e., 25,400 ± 28,200 ng/g). This further confirms that characteristics of the 
eNP (e.g. , functionality-pH responsive swelling; tumor localization; tumor specific drug 
release) are responsible for the improved tumor-specific and prolonged drug delivery 
resulting in improved overall survival. 
123 
4.6 Conclusion 
Pax has shown clinical success in a small set of patients in the management of 
mesothelioma, however current methods (i.e., bolus delivery) and routes of systemic (i.e., 
IV) or local (i.e., IP) administration are unable to take full advantage of Pax's therapeutic 
potential. In particular, maintenance of high tissue concentrations of Pax over prolonged 
periods is essential for maximizing its ability to effectively control and treat peritoneal 
mesothelioma. eNP delivery achieves high Pax concentrations by affording tumor-
specific accumulation and retention. Previously, we noted that several unmet challenges 
in IP drug delivery include the need for: 1) increased drug retention times in the IP cavity 
to allow exposure of more mitotic tumor cells and greater penetration into tumors; 2) 
enhanced tumor uptake of drug and intratumoral concentrations; and, 3) drug delivery 
systems that enhance tumor specific delivery and therein increase drug delivery into these 
cells. The Pax-eNP system described in this manuscript meets each of these criteria and, 
in so doing, is superior to Pax-C/E or Pax-PLGA-NPs in treating established IP 
mesothelioma. The superiority of Pax-eNPs is explained by data demonstrating the rapid 
accumulation of eNPs in IP tumors and, subsequently, the prolonged retention of IOOX's 
more Pax in tumor tissue three days following injection than is achieved via Pax-C/E 
treatments. Additionally, the in vitro comparison of Pax-eNPs vs. Pax-C/E using 
experiments designed to better reflect rapid pharmacokinetics and clearance of Pax 
demonstrate superiority of the eNP system in vitro that had been previously and 
paradoxically elusive while highlighting a piece of the mechanism behind Pax-eNP 
efficacy in vivo. 
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The significant benefits to local tumor tissue concentration and animal survival 
achieved using the eNP delivery system are striking. The selective accumulation in IP 
tumors, increase in local tissue concentration for prolonged periods compared to Pax 
delivered via C/E or PLGA-NPs, and the marked improvement in animal survival when 
treated with multiple doses of Pax-eNPs demonstrate that the unique, functional design of 
the eNP system is not simply another IP drug delivery system but, rather, a viable therapy 
for treating malignant peritoneal mesothelioma. 
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Figure 4.1 Schematic demonstrating the paradigm of expansile nanoparticle (eNP) 
mediated tumor-specific drug delivery to intraperitoneal (IP) mesothelioma tumors. 
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Figure 4.2 Cytotoxicity of Pax-eNPs against human malignant mesothelioma cells with a 
short treatment exposure time (4 hr). MST0-211H tumor cells were treated with Pax-
eNPs or equivalent concentrations of Pax-C/E for 4 hr, washed, and cultured for three 
days before cell viability was assessed via MTS assay. Pax-eNPs were significantly more 
potent than Pax-C/E (IC5o = 44.6 ng/mL vs. 1009 ng/mL, respectively). Unloaded-eNPs 
are not cytotoxic at any concentrations tested. (Data= mean± SD, n 2: 3). 
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Figure 4.3 Kinetics of PF-eNP localization to IP mesothelioma tumors in vivo. The PF-
eNPs emit bright white-blue light under UV -excitation. Top row: co-localization of PF-
eNPs and tumors (white circles) begins within 1-4 hr of IP injection. Bottom row: Live 
bioluminescent (left), post-mortem ambient light (middle), and ambient!UV light 
combination (right) indicate the co-localization of tumor burden (green circles) and PF-
eNPs (yellow circles). Images are representative of three animals at each time point. 
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Figure 4.4 Kinetics of cellular uptake of eNPs in malignant and healthy mesothelial cell 
lines. Cells were treated with Rho-eNPs for 0 hr (control), 2 hr, 8 hr, or 12 hr before 
washing and flow cytometric analysis. A) Rho-eNP signal increases rapidly (> 98%) 
within 2 hr of incubation in human-derived MST0-211H mesothelioma tumor cells. B) 
Rho-eNP uptake is slower (2% at 2 hr, 28% at 8 hr) in healthy mesothelial LP-3 cells. 
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Figure 4.5 Autophagosome accumulation in malignant MST0-211H cells resulting from 
eNP treatment as visualized by LC3-II accumulation. Cells were treated with A) 
chloroquine (positive control), B) Rho-eNPs (experimental), or C) media (negative 
control) for 24 h prior to fixation and staining. Rho-eNP treated cells exhibit similar LC3-
II distribution and accumulation as chloroquine treated cells. Untreated cells have 
minimal non-specific, non-punctate LC3-II signal. 
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Figure 4.6 Survival studies in a murine model of established IP mesothelioma. A) Four 
weekly doses of Pax-eNPs IP prolong overall survival in an established peritoneal tumor 
model. IP treatments (arrows) were initiated 7 d after 5 million MST0-211H-Luc cells 
were injected. Animals received 10 mg/kg Pax in Pax-eNPs, Pax-PLGA-NPs, or Pax-
CIE, or the matched control treatment including unloaded-eNPs, unloaded-PLGA-NPs, or 
saline. B) Impact of doubling Pax dose on overall survival. Animals received 4 doses of 
20 mg/kg Pax in Pax-eNPs or Pax-C/E, or unloaded-eNPs. C) Impact of doubling the 
number of doses and the duration of Pax on overall survival. Animals received 8 doses of 
10 mg/kg Pax in Pax-eNPs or Pax-C/E, or unloaded-eNPs. D) Summary of survival study 
data. 
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Figure 4. 7 Pax concentration A) and total amount B) within established tumor tissues 
harvested three days following a single IP treatment. Thirteen days after inoculation with 
MST0-211H tumor cells to establish bulky tumors, animals were injected IP with Pax-
eNPs (Pax= 10 mg/kg) or equivalent doses of Pax-PLGA-NPs or Pax-C/E. Three days 
after treatments, all visible tumors were dissected and harvested in a blind fashion 
without knowing the treatment group with Pax concentrations measured by LC/MS/MS. 
(* = P < 0.05) Significantly higher Pax concentrations and percent of injected dose were 
found in Pax-eNP treated animals compared to Pax-PLGA-NP or Pax-C/E treated 
animals. 
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CHAPTER 5. Intratumoral, Intracellular Drug Concentrating Polymeric 
Nanodevices 
5.1 Chapter Forward 
This chapter describes the in vitro and in vivo characterization of the "drug 
concentrating" effect exhibited by eNPs. In the course of discussion, we brought up the 
idea of reloading eNPs with paclitaxel (Pax) in situ-an idea which, if it could be 
demonstrated, offered the appeal of both practical application and intellectual novelty. 
From a practical standpoint, we envisioned that a system which could localize to a target 
tissue and then pull-in or concentrate a systemically administered agent into that tissue 
had two manifest advantages: 1) in the course of a multiple-treatment therapy, a patient 
could be dosed with significantly less polymer if the nanoparticles from the first injection 
could be reloaded with subsequent injections of drug (a likely safety benefit); and, 2) this 
therapy could be used in conjunction with current clinical practice wherein a single 
injection of particles prior to standard therapy would result in increased target tissue drug 
concentrations without needing to employ a treatment strategy foreign to medical 
oncologists. As an idea, it seems likely that groups working extensively with 
nanoparticles (NPs) may have already given this significant thought. However, since the 
paradigm ofNP-mediated drug delivery relies on encapsulation or covalent attachment of 
the drug to the carrier (i.e., NP), it seemed equally unlikely that significant pursuit of a 
delivery system involving the separate administration of drug and "carrier" had been 
undertaken. In fact, as discussed in the chapter, this idea of a "two-step" delivery is 
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unique to the field of NP-mediated delivery, though it has been investigated for some 
small molecule therapies in leukemia. This manuscript is currently in the midst of the 
submission process to Nature Nanotechnology. As with the other chapters, formatting is 
in accordance with the journal standards; however, in this case, due to the abbreviated 
"letter" format, I have introduced sub sections not present in the submitted version to 
assist in navigation through the chapter. 
5.2 Introduction 
Drug dose, high local target tissue concentration, and prolonged duration of exposure 
. 1 . . . hi . . 1 d £ 252-257 are essentta cntena m ac evmg optima rug per ormance. However, 
systemically delivered drugs often fail to effectively address these factors with only 
fractions of the injected dose reaching the target tissue. This is especially evident in the 
treatment of peritoneal cancers, including mesothelioma, ovarian, and pancreatic cancer, 
which regularly employ regimens of intravenous and/or intraperitoneal chemotherapy 
( . b' . 1 . d d 1' 1) . h 1' . d 1 258-260 e.g., gemc1ta me, c1sp atm, pemetrexe , an pac 1taxe w1t mte resu ts. Here, 
we show that a "two-step" nanoparticle (NP) delivery system may address this limitation. 
This two-step approach involves the separate administration of NP and drug where first 
the NP localizes to tumor. Second, subsequent administration of drug then rapidly 
concentrates into the NP already stationed within the target tissue. This two-step method 
results in a greater than 5-fold increase in intratumoral drug concentrations compared to 
conventional "drug-alone" administration. These results suggest that this 
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paradigmatically unique two-step delivery may provide a novel method for increasing 
target tissue drug concentrations. 
Paclitaxel (Pax) is one of several chemotherapeutic agents used in the treatment 
of peritoneal carcinomatoses. Although systemic side effects often persist for several 
days or even longer, 50% of an intraperitoneally (IP) injected dose of Pax is cleared 
within 3 h of administration affording only minimal drug concentration in the tumor and 
short drug-tumor exposure times?46 Overcoming this pharmacokinetic pattern of short 
drug exposure times and low drug concentrations presents a significant challenge to 
optimizing Pax delivery and efficacy. First, Pax is a cell cycle specific drug that acts only 
during cell replication; with only 1 0-15% of tumor cells expected to be in mitosis at any 
. . 1 p . d d . h h . 261-264 s d gtven time, tumora response to ax 1s re uce w1t s ort exposure times. econ , 
the mechanism of Pax antitumor activity is dependent on Pax concentration; when tumor 
cells are exposed to low concentrations of Pax, the cells enter a resting state where Pax is 
1 f :c: • • • ll d hi . 249 265-267 I . p no onger e 1ect1ve m causmg ce eat apoptosts. ' ncreasmg ax 
concentration directly within the tumor tissue is, therefore, a key challenge in oncology. 
We have developed a NP-based delivery system with the ability to concentrate 
separately administered drug in vivo and which may, therefore, overcome this challenge 
(Fig. 5.1, left). Such a drug concentrating system has the potential to afford high local 
drug levels within target tissues compared to drug alone treatments and represents a 
paradigm shift from conventional NP drug delivery systems involving administration of a 
drug encapsulated within or covalently bound to a NP. Specifically, using a human-
135 
derived mesothelioma cell line (MST0-211H) and an in vivo murine model of human 
peritoneal mesothelioma, we report: 1) the use of empty pH-responsive expansile 
nanoparticles (eNPs) to concentrate separately administered Pax in vitro; 2) the 
localization of fluorescently labeled eNPs to established in vivo mesothelioma tumors and 
subsequent co-localization of separately administered fluorescently labeled Pax; and, 3) 
the quantification of increased tumor tissue Pax concentrations after administration of 
eNPs followed by Pax compared to Pax alone and, poly(lactic-co-glycolic) acid (PLGA)-
NPs followed by Pax as a NP control. 
While the idea of using a "two-step" delivery system is new to the field of NP-
mediated drug delivery, it has been previously explored in other contexts, such as 
"b d d. d d. . h £ h . . 268-274 I h anti o y-me 1ate ra wunmunot erapy or ematop01etlc cancers. n t ese 
studies, a "targeting vehicle", such as a streptavidin labeled antibody, is administered and 
binds tightly to target cells due to the antibody-cell receptor interaction. "Target tissue-
specificity" can be increased by administration of a clearing agent, such as a biotinylated 
polymeric N-acetyl-galactos-amine conjugate, to increase excretion of any unbound 
antibody, although this is not necessary in systems which already exhibit rapid clearance 
of the streptavidin-antibody conjugate. Radiolabeled-biotin conjugate is subsequently 
administered, binding strongly to the streptavidin-antibody conjugate due to the high 
biotin-streptavidin affinity,275 and thus localizes the radiotherapy to the target cells in 
vivo while any unbound radiolabeled-biotin is rapidly cleared from the systemic 
circulation. Alternative approaches to "pre-targeted" radioimmunotherapy have also 
been described using hi-specific monovalent antibody-antihapten conjugates with similar 
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1 269 274 H b . 1 £ f "d" b" . . resu ts. ' owever, su optuna per ormance o streptav1 m- 1otm systems m vivo 
occurs due to the inability to effectively eliminate biotin from patient diets.276 
5.3 Methods 
5.3.1 General Procedures and Materials 
Nanoparticle formulations used in this study were prepared according to previously 
published procedures. 108' 244 For in vitro studies: complete growth media refers to RPMI 
supplemented with 10% fetal bovine serum (FBS) and 1% glutamine-penicillin-
streptomycin (GPS). Phosphate buffered saline (PBS) was used without calcium and 
magnesium supplementation unless otherwise noted. All cells were cultured at 3 7 oc 
with 5% C02 atmosphere. Media was replaced every other day during culture unless 
otherwise specified. All cell lines were used before passage 15. 
5.3.2 Fluorescence Microscopy ofPaxOG Concentration into eNP Pre-Treated Cells 
To confirm the intracellular drug concentrating capability of eNPs after two days of 
incubation with cells, we measured uptake of PaxOG in eNP pre-treated MST0-211H 
human mesothelioma cancer cells. MST0-211H cells were plated in 6-well plates at a 
density of 200,000 cells/well and allowed to adhere for 24 hr on #1.5 18 x 18 mm glass 
coverslips. The media was then removed and the cells were incubated for an additional 
48 hr with 2 mL media containing 50 )lg/mL (polymer concentration) eNPs or with media 
alone. The media was then aspirated and the cells were washed 2X with 2 mL PBS, and 
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incubated for 4 hr with media containing 25 flg/mL PaxOG. After 4 hr, the media was 
aspirated and the cells were washed 2X with 1 mL cold PBS, fixed in 3.7% formaldehyde 
for 20 minutes, and washed an additional 2X with 1 mL PBS and 2X with 1 mL PBS 
containing calcium and magnesium, then stained with 3 flg/mL Hoechst trihydrochloride 
trihydrate (nuclear stain) and 100 flg/mL Concanavalin A 633 conjugate (membrane 
stain) for 8 min. The cells were washed again 2X with 1 mL PBS containing calcium and 
magnesium and the coverslips then mounted on glass slides with Prolong Gold Anti-Fade 
reagent. Coverslips were imaged using a Zeiss LSM 510 meta inverted confocal 
microscope. 
5.3.3 In Vitro Quantification of Paclitaxel-Oregon Green (PaxOG) Concentration into 
eNP Pre-Treated Cells 
To quantify the intracellular drug concentrating capability of expansile 
nanoparticles (eNPs) after two days of incubation with cells, MST0-211H cells were 
plated in 96-well plates at a density of 2,000 cells/well and allowed to adhere for 24 hr. 
The media was then removed and the cells were incubated for an additional 48 hr with 
2 mL media containing 50 flg/mL (polymer concentration) eNPs or with media alone. 
The media was then aspirated and the cells were washed 2X with 2 mL PBS, and 
incubated for 4 hr with media containing 25 flg/mL PaxOG. After 4 hr, the media was 
aspirated and the cells were washed 2X with 1 mL cold PBS followed by lysing with 
100 ~-tL Promega Lysis Buffer lX. A fluorescence plate reader (Molecular Devices 
Spectra Max M5) was then used to measure fluorescence (!vex = 488 nm; Aem = 518 nm; 
cutoff filter 515 nm). All measurements were performed in at least triplicate. 
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5. 3. 4 In Vivo Characterization of Drug Concentration Via eNP Pre-Treatment 
Animal experiments were approved by the Institutional Animal Care and Use 
Committee and conducted in strict compliance with all federal and institutional 
guidelines. Intraperitoneal (IP) mesothelioma was established by IP injection of 5x 106 
MST0-211H-luciferase transfected cells in female, athymic, nude, 6-8 week old mice 
(Nu/J, Jackson Laboratory, Bar Harbor, ME). On day 11 following tumor cell injections, 
mice were randomized into two groups to receive IP injections of 0.3 mL of 20 J.!g/mL 
empty PF-eNPs or saline. Two days later (day 13), all mice received IP injections of 
10 mg/kg PaxOG-C/E in saline (6 mg/mL stock PaxOG-C/E diluted to 1 mg/mL with 
saline). Three days later, on day 16, all mice were euthanized. Upon sacrifice, the IP 
space was opened and examined using UV A 365 nm and UVC 254 nm light from a hand-
held Wood's lamp. 
5. 3. 5 In Vivo Quantification of Drug Concentration Via eNP Pre-Treatment 
Animal experiments were performed exactly as above but with un-labeled Pax and 
eNPs instead of PaxOG and PF -eNPs. IP mesothelioma was established by IP injection of 
5x106 MST0-211H-luciferase transfected cells in female, athymic, nude, 6-8 week old 
mice. On day 11 following tumor cell injections, mice were randomized into three groups 
to receive IP injections of 0.3 mL of 20 J.!g/mL empty eNPs, equivalent polymer weight 
of PLGA-NPs, or saline. Two days later (day 13), all mice received IP injections of 10 
mg/kg Pax-C/E in saline (6 mg/mL stock Pax-C/E diluted to 1 mg/mL with saline). Three 
days later, on day 16, all mice were euthanized. Upon sacrifice, all visible tumors in the 
IP space were dissected, harvested, weighted, then snap frozen, and stored at -80 oc for 
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Pax quantification. 
LC/MS/MS (Apredica Inc., Watertown, MA) was used to measure Pax 
concentrations within the tumor tissues. Pax was extracted from the tissue with three 
volumes of methanol containing an internal standard. This was centrifuged for 5 min at 
14,000 RPM to remove precipitated protein. The supernatant was collected and analyzed 
by LC/MS/MS using an Agilent 6410 mass spectrometer coupled with an Agilent 1200 
HPLC and a CTC PAL chilled auto sampler, controlled by MassHunter software 
(Agilent). After separation on a C18 reverse phase HPLC column (Agilent, Waters, or 
equivalent) using an acetonitrile-water gradient system, peaks were analyzed by mass 
spectrometry (MS) using ESI ionization in MRM mode. The limit of detection was 
40 ng/g. 
5.4 Results and Discussion 
In the current study, we use a 100 nrn pH-responsive NP composed of a cross-
linked polymer network that, upon cellular internalization and exposure to the mildly 
acidic (pH ~5) endosome, expands to afford a 1000 nrn hydrogel particle (i.e., expansile 
NP (eNP); Fig. 5.1, right). 108' 244 Additionally, Pax will partition into the expanded 
swollen eNPs :from the surrounding aqueous environment. 110 eNPs were synthesized 
using a previously reported, mini-emulsion, polymerization technique with the covalent 
incorporation of a fluorophore (either PolyFluor® 570, i.e. rhodamine, or PolyFluor® 
407) bl . l ki 108-109 244 A . . . l . . d £ d to ena e v1sua trac ng. ' n 1mtm m vztro stu y was per orme to 
confirm that eNPs would concentrate Pax into mesothelioma cells after a 48 hr co-
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incubation period. For these studies, MST0-211H human mesothelioma tumor cells were 
cultured under standard conditions prior to a "pre-treatment" co-incubation period of 
48 hr with media alone or with one of two unloaded-NP formulations (neither containing 
Pax): eNPs or PLGA-NPs (generic NP control). Paclitaxel labeled with Oregon Green 
(PaxOG) was then added to all cultures for 4 hr. Cells were washed 3X with phosphate 
buffered saline (PBS) to remove PaxOG adsorbed to the cell surface (Fig. 5.2, A). 
Confocal microscopy was used to confirm the intracellular accumulation of PaxOG and 
demonstrate co-localization with rhodamine-labeled eNPs (Rho-eNPs) in Rho-eNP pre-
treated cells (Fig. 5.2, B). To quantify internalized PaxOG, cells were washed, lysed and 
then the internalized PaxOG was measured with a fluorescent plate reader. Intracellular 
accumulation of PaxOG was nearly 5X greater in cells pre-treated with eNPs than in cells 
pre-treated with media or PLGA-NPs (Fig. 5.2, C). 
We next characterized the ability of eNPs to concentrate PaxOG into a tumor in 
vivo. Despite the absence of tumor-specific targeting ligands, previously published 
studies in murine models of established IP mesothelioma demonstrated that eNPs readily 
localize to areas of tumor in vivo. 109 Leveraging this eNP localization, we hypothesized 
that eNPs could be utilized to increase tumor tissue concentrations of separately 
administered Pax using a two step approach: 1) an initial dose of unloaded-eNPs that 
localizes to tumor and, 2) a second, separately injected dose of Pax which then 
concentrates within the tumor-associated eNPs. In order to simultaneously visualize the 
location of both eNPs and drug in situ, we fluorescently labeled eNPs with PolyFluor® 
407 (PF-eNPs) and used PaxOG. Selection of these two fluorophores allows separate 
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visualization of the PolyFluor® 407 (i.e., eNP) and Oregon Green (i.e., Pax) usmg 
254 run and 365 run wavelength UV light, respectively. These wavelengths (UVC and 
UV A, respectively) are readily obtained from a handheld Wood's lamp. Following the 
establishment of human MST0-211H tumors for 13 d in a murine model of peritoneal 
mesothelioma, unloaded-PF-eNPs were injected IP into three mice and allowed 48 hr to 
localize to the tumor tissue. Three control mice received an equivalent volume injection 
of saline. Forty-eight hours later, a single IP dose of 10 mg/kg PaxOG, solubilized in 
Cremophor/ethanol (C/E), was administered IP to all mice. Three days following PaxOG 
injection, mice were sacrificed and fluorescent imaging was utilized to identify the 
location of PF-eNP and PaxOG. Figure 5.3A displays representative images of PF-eNP 
vs. saline pre-treated mice immediately following sacrifice. Visible light images confirm 
that tumor was present in all animals and identifies the location of several large tumor 
nodules. In PF -eNP treated animals, 254 run UV light excitation demonstrates co-
localization of PF-eNPs within these tumor nodules and 365 run UV light excitation 
shows further co-localization of PaxOG with both the PF-eNPs and tumor nodules. In 
saline pre-treated mice, no PolyFluor® 407 (i.e. , eNP) signal was observed and PaxOG 
signal was not visibly detectable, consistent with the known rapid clearance of Pax in 
vivo. Furthermore, histological sections of tumor from each treatment group were imaged 
using confocal microscopy three days after PaxOG injection (Fig. 5.3B). Again, PaxOG 
and PF-eNPs are seen co-localized within the tumor microenvironment while PaxOG is 
not present or detected in the tumor tissue of animals receiving saline pre-treatments. 
Having confirmed qualitatively that fluorescently labeled eNPs concentrate 
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subsequently administered PaxOG into IP tumors, we quantified this effect usmg 
unlabeled-eNPs/Pax and liquid chromatography-triple quadrapole mass spectrometry 
(LC/MS/MS). The animals were treated exactly as before, with the exception that 
unlabeled-eNPs and conventional Pax were administered instead ofPF-eNPs and PaxOG. 
In addition, a treatment group receiving unloaded-PLGA-NPs was added to serve as a 
comparative generic NP control. Upon animal sacrifice 3 d after Pax IP injection, all 
visible tumor burden was harvested in a blinded fashion, followed by subsequent 
extraction and quantification of Pax by LC/MS/MS. Pre-treatment with eNPs 
significantly increased intra-tumoral concentrations of Pax compared to pre-treatment 
with either saline or PLGA-NPs (Fig. 5.4). The average Pax concentration within tumors 
in eNP pre-treated animals (2,341 ± 1,536 ng/g; N = 21) was significantly higher than the 
concentration in saline (439.2 ± 465.9 ng/g; N = 14) and PLGA-NP (487.2 ± 163.6 ng/g; 
N = 13) pretreated animals (P < 0.05 for eNP vs. PLGA-NP and eNP vs. saline; P = NS 
for PLGA-NP vs. saline). These results provide motivation for further studies on: 1) 
investigating the mechanism of Pax partitioning in the swollen eNPs via generation of a 
polymer hydrogel; 2) increasing Pax accumulation in the swollen eNP; and 3) evaluating 
the in vivo performance of this two-step approach. Based on published results from 
murine cancer models, a tissue concentration of ~20 f.A,gl g is sufficient to eliminate all 
detectable tumor,277 and this amount will serve as a target for our optimization studies. 
Nevertheless, even without optimization, this initial design serves as a robust proof-of-
concept with a greater than 5-fold increase in tumor tissue concentrations of Pax 
compared to the administration of Pax alone. 
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5.5 Conclusion 
The current study presents a new strategy for NP drug delivery wherein the carrier 
is used to subsequently concentrate systemically administered drug. Both the in vitro and 
in vivo results show a local increase in Pax concentration of 4-5X and, interestingly, this 
ability is not common among all NPs (as seen by the lack of drug concentration with 
PLGA-NPs). This approach represents a significant change from the current clinical 
regimen of a systemic bolus delivery of chemotherapy and also from the highly 
researched paradigm of NP-mediated (i.e. , encapsulated or covalently bound) drug 
delivery. This method provides a means to achieve a superior concentration of 
chemotherapy within the tumor and prolonged intra-tumoral drug exposure for a 
minimum of several days. 
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Figure 5.1 (Left) Schematic illustrating the paradigm shift to nanoparticle-mediated drug 
concentration of an agent to a tissue via: 1) a pre-treatment of unloaded particles followed 
by, 2) a subsequent separate administration of the agent (e.g. , paclitaxel) leading to 3) 
intratumoral accumulation of Pax (solid blue arrows) with release into surrounding tumor 
(hollow blue arrows). (Right) Chemical structure and mechanism of particle 
expansion/swelling following exposure to a mildly acidic aqueous environment. 
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Figure 5.2 In vitro characterization and quantification of the drug concentrating effect. 
A) Schematic illustration of the experimental design. B) Confocal microscopy images 
show PaxOG internalization in cells receiving a Rho-eNP pre-treatment. C) PaxOG 
uptake quantified via a fluorescent plate reader is significantly ( * = P < 0.01) increased in 
cells receiving a pre-treatment of eNPs compared to cells receiving media or PLGA-NP 
pre-treatments. 
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A) In situ imaging 
Figure 5.3 In vivo demonstration of the drug concentrating effect using PF -eNPs + 
PaxOG in a murine model of established IP mesothelioma. A) In PF-eNP pre-treated 
animals (top row), in situ imaging of the IP space under visible light reveals large tumor 
nodules (left), while imaging with 254 nm light shows PF-eNPs (middle) and 365 nm 
light reveals PaxOG (right) co-localized within tumor tissue. When saline is the pre-
treatment (bottom row) the blue PF-eNP signal is not observed and no PaxOG signal is 
seen in tumor tissues. B) Confocal microscopy of the tissues in A) confirms co-
localization of PF -eNPs and PaxOG within tumor tissue (blue-PF -eNP; green-PaxOG; 
red-nucleus) as well as absence of both PF -eNP and PaxOG in saline treated animals. 
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Figure 5.4 Quantification of the drug concentrating effect in vivo using eNPs + Pax in a 
murine model of established IP mesothelioma. Pax concentrations in the tumor tissue for 
eNP pre-treated animals (hashed blue) are significantly higher than in animals receiving 
a pre-treatment of saline (solid red) or PLGA-NPs (thatched orange)(*= P < 0.05). 
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SUMMARY 
New methods of drug delivery are required for treating patients who undergo 
theoretically "curative" surgical procedures but suffer from locally recurrent disease; the 
humanitarian and financial burden of this problem are devastating. We have developed a 
pH-responsive expansile nanoparticle (eNP) drug delivery system to improve the 
administration of a highly potent but poorly water-soluble chemotherapeutic agent, 
paclitaxel (Pax). We have characterized the functionality of the eNP system (i.e., pH- and 
time-dependent particle swelling and drug release) and elucidated the reasons for the 
limited success of Pax-eNPs in vitro compared to drug alone therapies. Furthermore, we 
have demonstrated that eNPs localize to regions of intraperitoneal (IP) mesothelioma in 
vivo and are significantly more effective (> 2X increase in median overall survival) in 
treating established IP disease than drug alone treatments. Lastly, we have shown in vitro 
and in vivo that eNPs can serve as drug concentrating devices that are able to sequester 
Pax from the surrounding aqueous environment and, in peritoneal mesothelioma, increase 
the tumoral concentrations of Pax over 5X compared to drug alone treatments. This work 
will further the development of novel drug delivery systems and may assist in the 
translation of eNPs into clinical use. 
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